Reviews - 2ajf mentioned but not cited (68)
- Origin and evolution of pathogenic coronaviruses. Cui J, Li F, Shi ZL. Nat Rev Microbiol 17 181-192 (2019)
- Characteristics of SARS-CoV-2 and COVID-19. Hu B, Guo H, Zhou P, Shi ZL. Nat Rev Microbiol 19 141-154 (2021)
- Structure, Function, and Evolution of Coronavirus Spike Proteins. Li F. Annu Rev Virol 3 237-261 (2016)
- SARS-CoV-2: Structure, Biology, and Structure-Based Therapeutics Development. Wang MY, Zhao R, Gao LJ, Gao XF, Wang DP, Cao JM. Front Cell Infect Microbiol 10 587269 (2020)
- Molecular Evolution of Human Coronavirus Genomes. Forni D, Cagliani R, Clerici M, Sironi M. Trends Microbiol 25 35-48 (2017)
- Receptor recognition mechanisms of coronaviruses: a decade of structural studies. Li F. J Virol 89 1954-1964 (2015)
- Subunit Vaccines Against Emerging Pathogenic Human Coronaviruses. Wang N, Shang J, Jiang S, Du L. Front Microbiol 11 298 (2020)
- Ready, set, fuse! The coronavirus spike protein and acquisition of fusion competence. Heald-Sargent T, Gallagher T. Viruses 4 557-580 (2012)
- From SARS to MERS: 10 years of research on highly pathogenic human coronaviruses. Hilgenfeld R, Peiris M. Antiviral Res 100 286-295 (2013)
- COVID-19 pandemic: Insights into structure, function, and hACE2 receptor recognition by SARS-CoV-2. Mittal A, Manjunath K, Ranjan RK, Kaushik S, Kumar S, Verma V. PLoS Pathog 16 e1008762 (2020)
- Inhibitors of SARS-CoV-2 Entry: Current and Future Opportunities. Xiu S, Dick A, Ju H, Mirzaie S, Abdi F, Cocklin S, Zhan P, Liu X. J Med Chem 63 12256-12274 (2020)
- Comprehensive Structural and Molecular Comparison of Spike Proteins of SARS-CoV-2, SARS-CoV and MERS-CoV, and Their Interactions with ACE2. Hatmal MM, Alshaer W, Al-Hatamleh MAI, Hatmal M, Smadi O, Taha MO, Oweida AJ, Boer JC, Mohamud R, Plebanski M. Cells 9 E2638 (2020)
- SARS-CoV and emergent coronaviruses: viral determinants of interspecies transmission. Bolles M, Donaldson E, Baric R. Curr Opin Virol 1 624-634 (2011)
- Cell entry by SARS-CoV-2. Peng R, Wu LA, Wang Q, Qi J, Gao GF. Trends Biochem Sci 46 848-860 (2021)
- Current advancements and potential strategies in the development of MERS-CoV vaccines. Zhang N, Jiang S, Du L. Expert Rev Vaccines 13 761-774 (2014)
- A review on drug repurposing applicable to COVID-19. Dotolo S, Marabotti A, Facchiano A, Tagliaferri R. Brief Bioinform 22 726-741 (2021)
- Receptor-binding domain-specific human neutralizing monoclonal antibodies against SARS-CoV and SARS-CoV-2. Yu F, Xiang R, Deng X, Wang L, Yu Z, Tian S, Liang R, Li Y, Ying T, Jiang S. Signal Transduct Target Ther 5 212 (2020)
- Chemistry and Biology of SARS-CoV-2. Dömling A, Gao L. Chem 6 1283-1295 (2020)
- Molecular diversity of coronavirus host cell entry receptors. Millet JK, Jaimes JA, Whittaker GR. FEMS Microbiol Rev 45 fuaa057 (2021)
- Coronavirus Disease Pandemic (COVID-19): Challenges and a Global Perspective. Malik YS, Kumar N, Sircar S, Kaushik R, Bhat S, Dhama K, Gupta P, Goyal K, Singh MP, Ghoshal U, El Zowalaty ME, O R V, Yatoo MI, Tiwari R, Pathak M, Patel SK, Sah R, Rodriguez-Morales AJ, Ganesh B, Kumar P, Singh RK. Pathogens 9 E519 (2020)
- Glycans of SARS-CoV-2 Spike Protein in Virus Infection and Antibody Production. Zhao X, Chen H, Wang H. Front Mol Biosci 8 629873 (2021)
- Déjà vu: Stimulating open drug discovery for SARS-CoV-2. Ekins S, Mottin M, Ramos PRPS, Sousa BKP, Neves BJ, Foil DH, Zorn KM, Braga RC, Coffee M, Southan C, Puhl AC, Andrade CH. Drug Discov Today 25 928-941 (2020)
- Airborne Transmission of COVID-19: Aerosol Dispersion, Lung Deposition, and Virus-Receptor Interactions. Zuo YY, Uspal WE, Wei T. ACS Nano 14 16502-16524 (2020)
- Structural Evaluation of the Spike Glycoprotein Variants on SARS-CoV-2 Transmission and Immune Evasion. Salleh MZ, Derrick JP, Deris ZZ. Int J Mol Sci 22 7425 (2021)
- Receptor-binding domain-based subunit vaccines against MERS-CoV. Zhang N, Tang J, Lu L, Jiang S, Du L. Virus Res 202 151-159 (2015)
- ACE2 and ACE: structure-based insights into mechanism, regulation and receptor recognition by SARS-CoV. Lubbe L, Cozier GE, Oosthuizen D, Acharya KR, Sturrock ED. Clin Sci (Lond) 134 2851-2871 (2020)
- A structural view of coronavirus-receptor interactions. Reguera J, Mudgal G, Santiago C, Casasnovas JM. Virus Res 194 3-15 (2014)
- SARS-CoV-2 Entry Inhibitors: Small Molecules and Peptides Targeting Virus or Host Cells. Cannalire R, Stefanelli I, Cerchia C, Beccari AR, Pelliccia S, Summa V. Int J Mol Sci 21 E5707 (2020)
- Blocking of the High-Affinity Interaction-Synapse Between SARS-CoV-2 Spike and Human ACE2 Proteins Likely Requires Multiple High-Affinity Antibodies: An Immune Perspective. Khatri I, Staal FJT, van Dongen JJM. Front Immunol 11 570018 (2020)
- COVID-19 endocrinopathy with hindsight from SARS. Kothandaraman N, Rengaraj A, Xue B, Yew WS, Velan SS, Karnani N, Leow MKS. Am J Physiol Endocrinol Metab 320 E139-E150 (2021)
- Effects of Glycosylation on the Enzymatic Activity and Mechanisms of Proteases. Goettig P. Int J Mol Sci 17 E1969 (2016)
- ACE2, the Receptor that Enables Infection by SARS-CoV-2: Biochemistry, Structure, Allostery and Evaluation of the Potential Development of ACE2 Modulators. Gross LZF, Sacerdoti M, Piiper A, Zeuzem S, Leroux AE, Biondi RM. ChemMedChem 15 1682-1690 (2020)
- Human coronavirus spike protein-host receptor recognition. Guruprasad L. Prog Biophys Mol Biol 161 39-53 (2021)
- Metal Complexes as Antiviral Agents for SARS-CoV-2. Karges J, Cohen SM. Chembiochem 22 2600-2607 (2021)
- Emerging viruses: Cross-species transmission of coronaviruses, filoviruses, henipaviruses, and rotaviruses from bats. Tian J, Sun J, Li D, Wang N, Wang L, Zhang C, Meng X, Ji X, Suchard MA, Zhang X, Lai A, Su S, Veit M. Cell Rep 39 110969 (2022)
- Therapeutics for COVID-19: from computation to practices-where we are, where we are heading to. Ojha PK, Kar S, Krishna JG, Roy K, Leszczynski J. Mol Divers 25 625-659 (2021)
- Artificial Intelligence Technologies for COVID-19 De Novo Drug Design. Floresta G, Zagni C, Gentile D, Patamia V, Rescifina A. Int J Mol Sci 23 3261 (2022)
- Bioengineering tools to speed up the discovery and preclinical testing of vaccines for SARS-CoV-2 and therapeutic agents for COVID-19. Raimondi MT, Donnaloja F, Barzaghini B, Bocconi A, Conci C, Parodi V, Jacchetti E, Carelli S. Theranostics 10 7034-7052 (2020)
- Molecular biology of the SARs-CoV-2 spike protein: A review of current knowledge. Zhu C, He G, Yin Q, Zeng L, Ye X, Shi Y, Xu W. J Med Virol 93 5729-5741 (2021)
- Spiking Pandemic Potential: Structural and Immunological Aspects of SARS-CoV-2. Wang YT, Landeras-Bueno S, Hsieh LE, Terada Y, Kim K, Ley K, Shresta S, Saphire EO, Regla-Nava JA. Trends Microbiol 28 605-618 (2020)
- 2020 update on human coronaviruses: One health, one world. Zhao X, Ding Y, Du J, Fan Y. Med Nov Technol Devices 8 100043 (2020)
- A comparative study of human betacoronavirus spike proteins: structure, function and therapeutics. Verma J, Subbarao N. Arch Virol 166 697-714 (2021)
- Key Considerations for the Development of Safe and Effective SARS-CoV-2 Subunit Vaccine: A Peptide-Based Vaccine Alternative. Shalash AO, Hussein WM, Skwarczynski M, Toth I. Adv Sci (Weinh) 8 e2100985 (2021)
- The impact of structural bioinformatics tools and resources on SARS-CoV-2 research and therapeutic strategies. Waman VP, Sen N, Varadi M, Daina A, Wodak SJ, Zoete V, Velankar S, Orengo C. Brief Bioinform 22 742-768 (2021)
- Natural and Nature-Derived Products Targeting Human Coronaviruses. Vougogiannopoulou K, Corona A, Tramontano E, Alexis MN, Skaltsounis AL. Molecules 26 448 (2021)
- The human pandemic coronaviruses on the show: The spike glycoprotein as the main actor in the coronaviruses play. Souza PFN, Mesquita FP, Amaral JL, Landim PGC, Lima KRP, Costa MB, Farias IR, Lima LB, Montenegro RC. Int J Biol Macromol 179 1-19 (2021)
- Molecular Docking as a Potential Approach in Repurposing Drugs Against COVID-19: a Systematic Review and Novel Pharmacophore Models. Fadlalla M, Ahmed M, Ali M, Elshiekh AA, Yousef BA. Curr Pharmacol Rep 8 212-226 (2022)
- A review of natural products, their effects on SARS-CoV-2 and their utility as lead compounds in the discovery of drugs for the treatment of COVID-19. Chapman RL, Andurkar SV. Med Chem Res 31 40-51 (2022)
- Roles, Characteristics, and Analysis of Intrinsically Disordered Proteins: A Minireview. Lermyte F. Life (Basel) 10 E320 (2020)
- Computational methods directed towards drug repurposing for COVID-19: advantages and limitations. Sharma PP, Bansal M, Sethi A, Poonam, Pena L, Goel VK, Grishina M, Chaturvedi S, Kumar D, Rathi B. RSC Adv 11 36181-36198 (2021)
- Elucidating the microscopic and computational techniques to study the structure and pathology of SARS-CoVs. Kaniyala Melanthota S, Banik S, Chakraborty I, Pallen S, Gopal D, Chakrabarti S, Mazumder N. Microsc Res Tech 83 1623-1638 (2020)
- The spike glycoprotein of highly pathogenic human coronaviruses: structural insights for understanding infection, evolution and inhibition. Qiao S, Zhang S, Ge J, Wang X. FEBS Open Bio 12 1602-1622 (2022)
- Advances in Targeting ACE2 for Developing COVID-19 Therapeutics. Suvarnapathaki S, Chauhan D, Nguyen A, Ramalingam M, Camci-Unal G. Ann Biomed Eng 50 1734-1749 (2022)
- How helpful were molecular dynamics simulations in shaping our understanding of SARS-CoV-2 spike protein dynamics? Abduljalil JM, Elghareib AM, Samir A, Ezat AA, Elfiky AA. Int J Biol Macromol 242 125153 (2023)
- Three-Dimensional Visualization of Viral Structure, Entry, and Replication Underlying the Spread of SARS-CoV-2. Saville JW, Berezuk AM, Srivastava SS, Subramaniam S. Chem Rev 122 14066-14084 (2022)
- Artemisia Extracts and Artemisinin-Based Antimalarials for COVID-19 Management: Could These Be Effective Antivirals for COVID-19 Treatment? Agrawal PK, Agrawal C, Blunden G. Molecules 27 3828 (2022)
- Host Receptors of Influenza Viruses and Coronaviruses-Molecular Mechanisms of Recognition. Sriwilaijaroen N, Suzuki Y. Vaccines (Basel) 8 E587 (2020)
- Human Coronavirus Cell Receptors Provide Challenging Therapeutic Targets. López-Cortés GI, Palacios-Pérez M, Hernández-Aguilar MM, Veledíaz HF, José MV. Vaccines (Basel) 11 174 (2023)
- Main and papain-like proteases as prospective targets for pharmacological treatment of coronavirus SARS-CoV-2. Yevsieieva LV, Lohachova KO, Kyrychenko A, Kovalenko SM, Ivanov VV, Kalugin ON. RSC Adv 13 35500-35524 (2023)
- The relevant information about the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) using the five-question approach (when, where, what, why, and how) and its impact on the environment. AlMalki FA, Albukhaty S, Alyamani AA, Khalaf MN, Thomas S. Environ Sci Pollut Res Int 30 61430-61454 (2023)
- Neutralizing monoclonal antibodies against highly pathogenic coronaviruses. Xiang R, Wang Y, Wang L, Deng X, Huo S, Jiang S, Yu F. Curr Opin Virol 53 101199 (2022)
- Towards Quantum-Chemical Level Calculations of SARS-CoV-2 Spike Protein Variants of Concern by First Principles Density Functional Theory. Ching WY, Adhikari P, Jawad B, Podgornik R. Biomedicines 11 517 (2023)
- Bioactive compounds as potential angiotensin-converting enzyme II inhibitors against COVID-19: a scoping review. de Matos PH, da Silva TP, Mansano AB, Gancedo NC, Tonin FS, Pelloso FC, Petruco MV, de Melo EB, Fernandez-Llimos F, Sanches ACC, de Mello JCP, Chierrito D, de Medeiros Araújo DC. Inflamm Res 71 1489-1500 (2022)
- Two years of SARS-CoV-2 infection (2019-2021): structural biology, vaccination, and current global situation. Ahmad W, Shabbiri K. Egypt J Intern Med 34 5 (2022)
- Anurans against SARS-CoV-2: A review of the potential antiviral action of anurans cutaneous peptides. de Amaral M, Ienes-Lima J. Virus Res 315 198769 (2022)
- Drug Weaponry to Fight Against SARS-CoV-2. Cabezón E, Arechaga I. Front Mol Biosci 7 204 (2020)
- Therapeutic nanobodies against SARS-CoV-2 and other pathogenic human coronaviruses. Yang Y, Li F, Du L. J Nanobiotechnology 22 304 (2024)
- The Three-Dimensional Reference Interaction Site Model Approach as a Promising Tool for Studying Hydrated Viruses and Their Complexes with Ligands. Fedotova MV, Chuev GN. Int J Mol Sci 25 3697 (2024)
Articles - 2ajf mentioned but not cited (266)
Reviews citing this publication (406)
- The trinity of COVID-19: immunity, inflammation and intervention. Tay MZ, Poh CM, Rénia L, MacAry PA, Ng LFP. Nat Rev Immunol 20 363-374 (2020)
- Extrapulmonary manifestations of COVID-19. Gupta A, Madhavan MV, Sehgal K, Nair N, Mahajan S, Sehrawat TS, Bikdeli B, Ahluwalia N, Ausiello JC, Wan EY, Freedberg DE, Kirtane AJ, Parikh SA, Maurer MS, Nordvig AS, Accili D, Bathon JM, Mohan S, Bauer KA, Leon MB, Krumholz HM, Uriel N, Mehra MR, Elkind MSV, Stone GW, Schwartz A, Ho DD, Bilezikian JP, Landry DW. Nat Med 26 1017-1032 (2020)
- Coronavirus biology and replication: implications for SARS-CoV-2. V'kovski P, Kratzel A, Steiner S, Stalder H, Thiel V. Nat Rev Microbiol 19 155-170 (2021)
- Mechanisms of SARS-CoV-2 entry into cells. Jackson CB, Farzan M, Chen B, Choe H. Nat Rev Mol Cell Biol 23 3-20 (2022)
- Angiotensin-Converting Enzyme 2: SARS-CoV-2 Receptor and Regulator of the Renin-Angiotensin System: Celebrating the 20th Anniversary of the Discovery of ACE2. Gheblawi M, Wang K, Viveiros A, Nguyen Q, Zhong JC, Turner AJ, Raizada MK, Grant MB, Oudit GY. Circ Res 126 1456-1474 (2020)
- Prevalence and impact of cardiovascular metabolic diseases on COVID-19 in China. Li B, Yang J, Zhao F, Zhi L, Wang X, Liu L, Bi Z, Zhao Y. Clin Res Cardiol 109 531-538 (2020)
- The spike protein of SARS-CoV--a target for vaccine and therapeutic development. Du L, He Y, Zhou Y, Liu S, Zheng BJ, Jiang S. Nat Rev Microbiol 7 226-236 (2009)
- The molecular biology of coronaviruses. Masters PS. Adv Virus Res 66 193-292 (2006)
- Role of angiotensin-converting enzyme 2 (ACE2) in COVID-19. Ni W, Yang X, Yang D, Bao J, Li R, Xiao Y, Hou C, Wang H, Liu J, Yang D, Xu Y, Cao Z, Gao Z. Crit Care 24 422 (2020)
- From SARS to MERS, Thrusting Coronaviruses into the Spotlight. Song Z, Xu Y, Bao L, Zhang L, Yu P, Qu Y, Zhu H, Zhao W, Han Y, Qin C. Viruses 11 E59 (2019)
- Host cell proteases: Critical determinants of coronavirus tropism and pathogenesis. Millet JK, Whittaker GR. Virus Res 202 120-134 (2015)
- Severe acute respiratory syndrome coronavirus as an agent of emerging and reemerging infection. Cheng VC, Lau SK, Woo PC, Yuen KY. Clin Microbiol Rev 20 660-694 (2007)
- Coronavirus membrane fusion mechanism offers a potential target for antiviral development. Tang T, Bidon M, Jaimes JA, Whittaker GR, Daniel S. Antiviral Res 178 104792 (2020)
- Coronavirus pathogenesis. Weiss SR, Leibowitz JL. Adv Virus Res 81 85-164 (2011)
- Recombination, reservoirs, and the modular spike: mechanisms of coronavirus cross-species transmission. Graham RL, Baric RS. J Virol 84 3134-3146 (2010)
- A decade after SARS: strategies for controlling emerging coronaviruses. Graham RL, Donaldson EF, Baric RS. Nat Rev Microbiol 11 836-848 (2013)
- Bat-to-human: spike features determining 'host jump' of coronaviruses SARS-CoV, MERS-CoV, and beyond. Lu G, Wang Q, Gao GF. Trends Microbiol 23 468-478 (2015)
- The Natural History, Pathobiology, and Clinical Manifestations of SARS-CoV-2 Infections. Machhi J, Herskovitz J, Senan AM, Dutta D, Nath B, Oleynikov MD, Blomberg WR, Meigs DD, Hasan M, Patel M, Kline P, Chang RC, Chang L, Gendelman HE, Kevadiya BD. J Neuroimmune Pharmacol 15 359-386 (2020)
- The emerging role of ACE2 in physiology and disease. Hamming I, Cooper ME, Haagmans BL, Hooper NM, Korstanje R, Osterhaus AD, Timens W, Turner AJ, Navis G, van Goor H. J Pathol 212 1-11 (2007)
- The molecular virology of coronaviruses. Hartenian E, Nandakumar D, Lari A, Ly M, Tucker JM, Glaunsinger BA. J Biol Chem 295 12910-12934 (2020)
- Trilogy of ACE2: a peptidase in the renin-angiotensin system, a SARS receptor, and a partner for amino acid transporters. Kuba K, Imai Y, Ohto-Nakanishi T, Penninger JM. Pharmacol Ther 128 119-128 (2010)
- COVID-19: Epidemiology, Evolution, and Cross-Disciplinary Perspectives. Sun J, He WT, Wang L, Lai A, Ji X, Zhai X, Li G, Suchard MA, Tian J, Zhou J, Veit M, Su S. Trends Mol Med 26 483-495 (2020)
- Targeting the NLRP3 Inflammasome in Severe COVID-19. Freeman TL, Swartz TH. Front Immunol 11 1518 (2020)
- Coronavirus Spike Protein and Tropism Changes. Hulswit RJ, de Haan CA, Bosch BJ. Adv Virus Res 96 29-57 (2016)
- Proteolytic activation of the SARS-coronavirus spike protein: cutting enzymes at the cutting edge of antiviral research. Simmons G, Zmora P, Gierer S, Heurich A, Pöhlmann S. Antiviral Res 100 605-614 (2013)
- Bat origin of human coronaviruses. Hu B, Ge X, Wang LF, Shi Z. Virol J 12 221 (2015)
- Comparative Review of SARS-CoV-2, SARS-CoV, MERS-CoV, and Influenza A Respiratory Viruses. Abdelrahman Z, Li M, Wang X. Front Immunol 11 552909 (2020)
- T-cell immunity of SARS-CoV: Implications for vaccine development against MERS-CoV. Liu WJ, Zhao M, Liu K, Xu K, Wong G, Tan W, Gao GF. Antiviral Res 137 82-92 (2017)
- ACE2: Evidence of role as entry receptor for SARS-CoV-2 and implications in comorbidities. Zamorano Cuervo N, Grandvaux N. Elife 9 e61390 (2020)
- An overview of COVID-19. Shi Y, Wang G, Cai XP, Deng JW, Zheng L, Zhu HH, Zheng M, Yang B, Chen Z. J Zhejiang Univ Sci B 21 343-360 (2020)
- MERS-CoV spike protein: a key target for antivirals. Du L, Yang Y, Zhou Y, Lu L, Li F, Jiang S. Expert Opin Ther Targets 21 131-143 (2017)
- Mesenchymal Stem Cell Therapy for COVID-19: Present or Future. Golchin A, Seyedjafari E, Ardeshirylajimi A. Stem Cell Rev Rep 16 427-433 (2020)
- Animal origins of the severe acute respiratory syndrome coronavirus: insight from ACE2-S-protein interactions. Li W, Wong SK, Li F, Kuhn JH, Huang IC, Choe H, Farzan M. J Virol 80 4211-4219 (2006)
- Therapeutic strategies in an outbreak scenario to treat the novel coronavirus originating in Wuhan, China. Kruse RL. F1000Res 9 72 (2020)
- Domains and Functions of Spike Protein in Sars-Cov-2 in the Context of Vaccine Design. Xia X. Viruses 13 109 (2021)
- Role of Oxidative Stress on SARS-CoV (SARS) and SARS-CoV-2 (COVID-19) Infection: A Review. Suhail S, Zajac J, Fossum C, Lowater H, McCracken C, Severson N, Laatsch B, Narkiewicz-Jodko A, Johnson B, Liebau J, Bhattacharyya S, Hati S. Protein J 39 644-656 (2020)
- A review of studies on animal reservoirs of the SARS coronavirus. Shi Z, Hu Z. Virus Res 133 74-87 (2008)
- COVID-19, Renin-Angiotensin System and Endothelial Dysfunction. Amraei R, Rahimi N. Cells 9 E1652 (2020)
- Mesenchymal Stem Cell-Derived Exosomes: Applications in Regenerative Medicine. Hade MD, Suire CN, Suo Z. Cells 10 1959 (2021)
- The COVID-19 Vaccine Race: Challenges and Opportunities in Vaccine Formulation. Wang J, Peng Y, Xu H, Cui Z, Williams RO. AAPS PharmSciTech 21 225 (2020)
- COVID-19 Outbreak: An Overview. Ciotti M, Angeletti S, Minieri M, Giovannetti M, Benvenuto D, Pascarella S, Sagnelli C, Bianchi M, Bernardini S, Ciccozzi M. Chemotherapy 64 215-223 (2019)
- Nanotechnology for COVID-19: Therapeutics and Vaccine Research. Chauhan G, Madou MJ, Kalra S, Chopra V, Ghosh D, Martinez-Chapa SO. ACS Nano 14 7760-7782 (2020)
- Molecular mechanism of interaction between SARS-CoV-2 and host cells and interventional therapy. Zhang Q, Xiang R, Huo S, Zhou Y, Jiang S, Wang Q, Yu F. Signal Transduct Target Ther 6 233 (2021)
- ACE2, TMPRSS2 distribution and extrapulmonary organ injury in patients with COVID-19. Dong M, Zhang J, Ma X, Tan J, Chen L, Liu S, Xin Y, Zhuang L. Biomed Pharmacother 131 110678 (2020)
- Novel Therapeutic Approaches Targeting the Renin-Angiotensin System and Associated Peptides in Hypertension and Heart Failure. Arendse LB, Danser AHJ, Poglitsch M, Touyz RM, Burnett JC, Llorens-Cortes C, Ehlers MR, Sturrock ED. Pharmacol Rev 71 539-570 (2019)
- Receptor recognition and cross-species infections of SARS coronavirus. Li F. Antiviral Res 100 246-254 (2013)
- ACE2 - from the renin-angiotensin system to gut microbiota and malnutrition. Perlot T, Penninger JM. Microbes Infect 15 866-873 (2013)
- Emerging SARS-CoV-2 variants of concern and potential intervention approaches. Khateeb J, Li Y, Zhang H. Crit Care 25 244 (2021)
- The role of extracellular vesicles in COVID-19 virus infection. Hassanpour M, Rezaie J, Nouri M, Panahi Y. Infect Genet Evol 85 104422 (2020)
- Inflammation Triggered by SARS-CoV-2 and ACE2 Augment Drives Multiple Organ Failure of Severe COVID-19: Molecular Mechanisms and Implications. Iwasaki M, Saito J, Zhao H, Sakamoto A, Hirota K, Ma D, Ma D. Inflammation 44 13-34 (2021)
- Coronavirus Disease 2019 and Stroke: Clinical Manifestations and Pathophysiological Insights. Divani AA, Andalib S, Di Napoli M, Lattanzi S, Hussain MS, Biller J, McCullough LD, Azarpazhooh MR, Seletska A, Mayer SA, Torbey M. J Stroke Cerebrovasc Dis 29 104941 (2020)
- Post-translational modifications of coronavirus proteins: roles and function. Fung TS, Liu DX. Future Virol 13 405-430 (2018)
- Epidemiology, pathogenesis, clinical presentations, diagnosis and treatment of COVID-19: a review of current evidence. Rahman S, Montero MTV, Rowe K, Kirton R, Kunik F. Expert Rev Clin Pharmacol 14 601-621 (2021)
- The first, holistic immunological model of COVID-19: Implications for prevention, diagnosis, and public health measures. Matricardi PM, Dal Negro RW, Nisini R. Pediatr Allergy Immunol 31 454-470 (2020)
- SARS-CoV-2 jumping the species barrier: Zoonotic lessons from SARS, MERS and recent advances to combat this pandemic virus. Dhama K, Patel SK, Sharun K, Pathak M, Tiwari R, Yatoo MI, Malik YS, Sah R, Rabaan AA, Panwar PK, Singh KP, Michalak I, Chaicumpa W, Martinez-Pulgarin DF, Bonilla-Aldana DK, Rodriguez-Morales AJ. Travel Med Infect Dis 37 101830 (2020)
- Dexamethasone for the Treatment of Coronavirus Disease (COVID-19): a Review. Ahmed MH, Hassan A. SN Compr Clin Med 2 2637-2646 (2020)
- Structure of SARS-CoV-2 spike protein. Zhang J, Xiao T, Cai Y, Chen B. Curr Opin Virol 50 173-182 (2021)
- Infectious diseases emerging from Chinese wet-markets: zoonotic origins of severe respiratory viral infections. Woo PC, Lau SK, Yuen KY. Curr Opin Infect Dis 19 401-407 (2006)
- Interaction of SARS-CoV-2 and Other Coronavirus With ACE (Angiotensin-Converting Enzyme)-2 as Their Main Receptor: Therapeutic Implications. Davidson AM, Wysocki J, Batlle D. Hypertension 76 1339-1349 (2020)
- Severe respiratory SARS-CoV2 infection: Does ACE2 receptor matter? Perrotta F, Matera MG, Cazzola M, Bianco A. Respir Med 168 105996 (2020)
- Diagnosis of COVID-19 for controlling the pandemic: A review of the state-of-the-art. Taleghani N, Taghipour F. Biosens Bioelectron 174 112830 (2021)
- Structure-based antigen design: a strategy for next generation vaccines. Dormitzer PR, Ulmer JB, Rappuoli R. Trends Biotechnol 26 659-667 (2008)
- SARS-CoV-2, the pandemic coronavirus: Molecular and structural insights. Kadam SB, Sukhramani GS, Bishnoi P, Pable AA, Barvkar VT. J Basic Microbiol 61 180-202 (2021)
- COVID-19 vaccine: where are we now and where should we go? Soleimanpour S, Yaghoubi A. Expert Rev Vaccines 20 23-44 (2021)
- Two important controversial risk factors in SARS-CoV-2 infection: Obesity and smoking. Engin AB, Engin ED, Engin A. Environ Toxicol Pharmacol 78 103411 (2020)
- ABO blood group and COVID-19: a review on behalf of the ISBT COVID-19 Working Group. Goel R, Bloch EM, Pirenne F, Al-Riyami AZ, Crowe E, Dau L, Land K, Townsend M, Jecko T, Rahimi-Levene N, Patidar G, Josephson CD, Arora S, Vermeulen M, Vrielink H, Montemayor C, Oreh A, Hindawi S, van den Berg K, Serrano K, So-Osman C, Wood E, Devine DV, Spitalnik SL, ISBT COVID-19 Working Group. Vox Sang 116 849-861 (2021)
- Advances in research on ACE2 as a receptor for 2019-nCoV. Wu J, Deng W, Li S, Yang X. Cell Mol Life Sci 78 531-544 (2021)
- The NLRP3 inflammasome and COVID-19: Activation, pathogenesis and therapeutic strategies. Zhao N, Di B, Xu LL. Cytokine Growth Factor Rev 61 2-15 (2021)
- Vaccines for the prevention against the threat of MERS-CoV. Du L, Tai W, Zhou Y, Jiang S. Expert Rev Vaccines 15 1123-1134 (2016)
- Targeting TNF-α for COVID-19: Recent Advanced and Controversies. Guo Y, Hu K, Li Y, Lu C, Ling K, Cai C, Wang W, Ye D. Front Public Health 10 833967 (2022)
- SARS-CoV-2 and nervous system: From pathogenesis to clinical manifestation. Keyhanian K, Umeton RP, Mohit B, Davoudi V, Hajighasemi F, Ghasemi M. J Neuroimmunol 350 577436 (2020)
- Supramolecular Architecture of the Coronavirus Particle. Neuman BW, Buchmeier MJ. Adv Virus Res 96 1-27 (2016)
- MERS-CoV spike protein: Targets for vaccines and therapeutics. Wang Q, Wong G, Lu G, Yan J, Gao GF. Antiviral Res 133 165-177 (2016)
- The molecular biology of SARS coronavirus. Satija N, Lal SK. Ann N Y Acad Sci 1102 26-38 (2007)
- Structure and Function of Major SARS-CoV-2 and SARS-CoV Proteins. Gorkhali R, Koirala P, Rijal S, Mainali A, Baral A, Bhattarai HK. Bioinform Biol Insights 15 11779322211025876 (2021)
- Cell entry by enveloped viruses: redox considerations for HIV and SARS-coronavirus. Fenouillet E, Barbouche R, Jones IM. Antioxid Redox Signal 9 1009-1034 (2007)
- Emergence of Novel Coronavirus 2019-nCoV: Need for Rapid Vaccine and Biologics Development. Shanmugaraj B, Malla A, Phoolcharoen W. Pathogens 9 E148 (2020)
- Three key proteases--angiotensin-I-converting enzyme (ACE), ACE2 and renin--within and beyond the renin-angiotensin system. Guang C, Phillips RD, Jiang B, Milani F. Arch Cardiovasc Dis 105 373-385 (2012)
- Angiotensin-converting enzyme 2 in severe acute respiratory syndrome coronavirus and SARS-CoV-2: A double-edged sword? Yan T, Xiao R, Lin G. FASEB J 34 6017-6026 (2020)
- Crosstalk between the renin-angiotensin, complement and kallikrein-kinin systems in inflammation. Bekassy Z, Lopatko Fagerström I, Bader M, Karpman D. Nat Rev Immunol 22 411-428 (2022)
- Virology, pathogenesis, diagnosis and in-line treatment of COVID-19. Samudrala PK, Kumar P, Choudhary K, Thakur N, Wadekar GS, Dayaramani R, Agrawal M, Alexander A. Eur J Pharmacol 883 173375 (2020)
- COVID-19 Vaccines: "Warp Speed" Needs Mind Melds, Not Warped Minds. Moore JP, Klasse PJ. J Virol 94 e01083-20 (2020)
- Pathophysiological characteristics and therapeutic approaches for pulmonary injury and cardiovascular complications of coronavirus disease 2019. Geng YJ, Wei ZY, Qian HY, Huang J, Lodato R, Castriotta RJ. Cardiovasc Pathol 47 107228 (2020)
- Timing is everything: Fine-tuned molecular machines orchestrate paramyxovirus entry. Bose S, Jardetzky TS, Lamb RA. Virology 479-480 518-531 (2015)
- SARS-CoV-2 mediated neuroinflammation and the impact of COVID-19 in neurological disorders. Amruta N, Chastain WH, Paz M, Solch RJ, Murray-Brown IC, Befeler JB, Gressett TE, Longo MT, Engler-Chiurazzi EB, Bix G. Cytokine Growth Factor Rev 58 1-15 (2021)
- ACE2 in the Era of SARS-CoV-2: Controversies and Novel Perspectives. Saponaro F, Rutigliano G, Sestito S, Bandini L, Storti B, Bizzarri R, Zucchi R. Front Mol Biosci 7 588618 (2020)
- Smoking and COVID-19: What we know so far. Shastri MD, Shukla SD, Chong WC, Kc R, Dua K, Patel RP, Peterson GM, O'Toole RF. Respir Med 176 106237 (2021)
- Neutralizing human monoclonal antibodies to severe acute respiratory syndrome coronavirus: target, mechanism of action, and therapeutic potential. Coughlin MM, Prabhakar BS. Rev Med Virol 22 2-17 (2012)
- Development of animal models against emerging coronaviruses: From SARS to MERS coronavirus. Sutton TC, Subbarao K. Virology 479-480 247-258 (2015)
- An Insight into the Sex Differences in COVID-19 Patients: What are the Possible Causes? Maleki Dana P, Sadoughi F, Hallajzadeh J, Asemi Z, Mansournia MA, Yousefi B, Momen-Heravi M. Prehosp Disaster Med 35 438-441 (2020)
- Discovering small-molecule therapeutics against SARS-CoV-2. Tiwari V, Beer JC, Sankaranarayanan NV, Swanson-Mungerson M, Desai UR. Drug Discov Today 25 1535-1544 (2020)
- Analysis of COVID-19 vaccines: Types, thoughts, and application. Han X, Xu P, Ye Q. J Clin Lab Anal 35 e23937 (2021)
- Angiotensin-converting enzyme 2 and new insights into the renin-angiotensin system. Lambert DW, Hooper NM, Turner AJ. Biochem Pharmacol 75 781-786 (2008)
- Mutations of SARS-CoV-2 spike protein: Implications on immune evasion and vaccine-induced immunity. Mengist HM, Kombe Kombe AJ, Mekonnen D, Abebaw A, Getachew M, Jin T. Semin Immunol 55 101533 (2021)
- Structural insights into SARS coronavirus proteins. Bartlam M, Yang H, Rao Z. Curr Opin Struct Biol 15 664-672 (2005)
- Structure and mechanism of metallocarboxypeptidases. Gomis-Rüth FX. Crit Rev Biochem Mol Biol 43 319-345 (2008)
- Animal models for SARS-CoV-2 research: A comprehensive literature review. Pandey K, Acharya A, Mohan M, Ng CL, Reid SP, Byrareddy SN. Transbound Emerg Dis 68 1868-1885 (2021)
- SARS coronavirus 2: from genome to infectome. Rastogi M, Pandey N, Shukla A, Singh SK. Respir Res 21 318 (2020)
- Severe Acute Lung Injury Related to COVID-19 Infection: A Review and the Possible Role for Escin. Gallelli L, Zhang L, Wang T, Fu F, Fu F. J Clin Pharmacol 60 815-825 (2020)
- SARS-CoV-2 Infection: New Molecular, Phylogenetic, and Pathogenetic Insights. Efficacy of Current Vaccines and the Potential Risk of Variants. Rotondo JC, Martini F, Maritati M, Mazziotta C, Di Mauro G, Lanzillotti C, Barp N, Gallerani A, Tognon M, Contini C. Viruses 13 1687 (2021)
- Diabetes and COVID-19: The past, the present, and the future. Pranata R, Henrina J, Raffaello WM, Lawrensia S, Huang I. Metabolism 121 154814 (2021)
- Vasculopathy and Coagulopathy Associated with SARS-CoV-2 Infection. Labò N, Ohnuki H, Tosato G. Cells 9 E1583 (2020)
- Functional importance of the D614G mutation in the SARS-CoV-2 spike protein. Jackson CB, Zhang L, Farzan M, Choe H. Biochem Biophys Res Commun 538 108-115 (2021)
- New insights into the roles of metalloproteinases in neurodegeneration and neuroprotection. Turner AJ, Nalivaeva NN. Int Rev Neurobiol 82 113-135 (2007)
- Prospects for RNAi Therapy of COVID-19. Uludağ H, Parent K, Aliabadi HM, Haddadi A. Front Bioeng Biotechnol 8 916 (2020)
- Structural Analysis of Neutralizing Epitopes of the SARS-CoV-2 Spike to Guide Therapy and Vaccine Design Strategies. Finkelstein MT, Mermelstein AG, Parker Miller E, Seth PC, Stancofski ED, Fera D. Viruses 13 134 (2021)
- COVID-19 Therapeutic Options Under Investigation. Kaddoura M, AlIbrahim M, Hijazi G, Soudani N, Audi A, Alkalamouni H, Haddad S, Eid A, Zaraket H. Front Pharmacol 11 1196 (2020)
- COVID-19 preclinical models: human angiotensin-converting enzyme 2 transgenic mice. Lutz C, Maher L, Lee C, Kang W. Hum Genomics 14 20 (2020)
- Prevalence of Diabetes and Hypertension and Their Associated Risks for Poor Outcomes in Covid-19 Patients. Barrera FJ, Shekhar S, Wurth R, Moreno-Pena PJ, Ponce OJ, Hajdenberg M, Alvarez-Villalobos NA, Hall JE, Schiffrin EL, Eisenhofer G, Porter F, Brito JP, Bornstein SR, Stratakis CA, González-González JG, Rodíguez-Gutiérrez R, Hannah-Shmouni F. J Endocr Soc 4 bvaa102 (2020)
- SARS-CoV-2 entry in host cells-multiple targets for treatment and prevention. Mahmoud IS, Jarrar YB, Alshaer W, Ismail S. Biochimie 175 93-98 (2020)
- SARS-CoV-2 Delta (B.1.617.2) Variant: A Unique T478K Mutation in Receptor Binding Motif (RBM) of Spike Gene. Jhun H, Park HY, Hisham Y, Song CS, Kim S. Immune Netw 21 e32 (2021)
- Host-pathogen interaction in COVID-19: Pathogenesis, potential therapeutics and vaccination strategies. Varghese PM, Tsolaki AG, Yasmin H, Shastri A, Ferluga J, Vatish M, Madan T, Kishore U. Immunobiology 225 152008 (2020)
- SARS-CoV-2, COVID-19, skin and immunology - What do we know so far? Novak N, Peng W, Naegeli MC, Galvan C, Kolm-Djamei I, Brüggen C, Cabanillas B, Schmid-Grendelmeier P, Catala A. Allergy 76 698-713 (2021)
- The 2020 Pandemic: Current SARS-CoV-2 Vaccine Development. Alturki SO, Alturki SO, Connors J, Cusimano G, Kutzler MA, Izmirly AM, Haddad EK. Front Immunol 11 1880 (2020)
- A rational roadmap for SARS-CoV-2/COVID-19 pharmacotherapeutic research and development: IUPHAR Review 29. Alexander SPH, Armstrong JF, Davenport AP, Davies JA, Faccenda E, Harding SD, Levi-Schaffer F, Maguire JJ, Pawson AJ, Southan C, Spedding M. Br J Pharmacol 177 4942-4966 (2020)
- Neurotropism of SARS-CoV-2 and its neuropathological alterations: Similarities with other coronaviruses. Hu J, Jolkkonen J, Zhao C. Neurosci Biobehav Rev 119 184-193 (2020)
- Plant-Based COVID-19 Vaccines: Current Status, Design, and Development Strategies of Candidate Vaccines. Maharjan PM, Choe S. Vaccines (Basel) 9 992 (2021)
- l-Arginine and COVID-19: An Update. Adebayo A, Varzideh F, Wilson S, Gambardella J, Eacobacci M, Jankauskas SS, Donkor K, Kansakar U, Trimarco V, Mone P, Lombardi A, Santulli G. Nutrients 13 3951 (2021)
- Biosensors for the Determination of SARS-CoV-2 Virus and Diagnosis of COVID-19 Infection. Drobysh M, Ramanaviciene A, Viter R, Chen CF, Samukaite-Bubniene U, Ratautaite V, Ramanavicius A. Int J Mol Sci 23 666 (2022)
- Natural Infection by SARS-CoV-2 in Companion Animals: A Review of Case Reports and Current Evidence of Their Role in the Epidemiology of COVID-19. de Morais HA, Dos Santos AP, do Nascimento NC, Kmetiuk LB, Barbosa DS, Brandão PE, Guimarães AMS, Pettan-Brewer C, Biondo AW. Front Vet Sci 7 591216 (2020)
- Potent human monoclonal antibodies against SARS CoV, Nipah and Hendra viruses. Prabakaran P, Zhu Z, Xiao X, Biragyn A, Dimitrov AS, Broder CC, Dimitrov DS. Expert Opin Biol Ther 9 355-368 (2009)
- Promising Extracellular Vesicle-Based Vaccines against Viruses, Including SARS-CoV-2. Sabanovic B, Piva F, Cecati M, Giulietti M. Biology (Basel) 10 94 (2021)
- Small molecules in the treatment of COVID-19. Lei S, Chen X, Wu J, Duan X, Men K. Signal Transduct Target Ther 7 387 (2022)
- Potential Natural Products Against Respiratory Viruses: A Perspective to Develop Anti-COVID-19 Medicines. Omrani M, Keshavarz M, Nejad Ebrahimi S, Mehrabi M, McGaw LJ, Ali Abdalla M, Mehrbod P. Front Pharmacol 11 586993 (2020)
- SARS molecular epidemiology: a Chinese fairy tale of controlling an emerging zoonotic disease in the genomics era. Zhao GP. Philos Trans R Soc Lond B Biol Sci 362 1063-1081 (2007)
- The Nrf2 Activator (DMF) and Covid-19: Is there a Possible Role? Hassan SM, Jawad MJ, Ahjel SW, Singh RB, Singh J, Awad SM, Hadi NR. Med Arch 74 134-138 (2020)
- A Comprehensive Review about the Molecular Structure of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2): Insights into Natural Products against COVID-19. Saied EM, El-Maradny YA, Osman AA, Darwish AMG, Abo Nahas HH, Niedbała G, Piekutowska M, Abdel-Rahman MA, Balbool BA, Abdel-Azeem AM. Pharmaceutics 13 1759 (2021)
- SARS-CoV-2 Omicron Mutation Is Faster than the Chase: Multiple Mutations on Spike/ACE2 Interaction Residues. Kim S, Nguyen TT, Taitt AS, Jhun H, Park HY, Park HY, Kim SH, Kim YG, Song EY, Lee Y, Yum H, Shin KC, Choi YK, Song CS, Yeom SC, Kim B, Netea M, Kim S. Immune Netw 21 e38 (2021)
- Affinity Sensors for the Diagnosis of COVID-19. Drobysh M, Ramanaviciene A, Viter R, Ramanavicius A. Micromachines (Basel) 12 390 (2021)
- Anti-COVID-19 drug candidates: A review on potential biological activities of natural products in the management of new coronavirus infection. Prasansuklab A, Theerasri A, Rangsinth P, Sillapachaiyaporn C, Chuchawankul S, Tencomnao T. J Tradit Complement Med 11 144-157 (2021)
- Antiviral Drug Discovery for the Treatment of COVID-19 Infections. Ng TI, Correia I, Seagal J, DeGoey DA, Schrimpf MR, Hardee DJ, Noey EL, Kati WM. Viruses 14 961 (2022)
- Minireview of progress in the structural study of SARS-CoV-2 proteins. Zhu G, Zhu C, Zhu Y, Sun F. Curr Res Microb Sci 1 53-61 (2020)
- Origin, Potential Therapeutic Targets and Treatment for Coronavirus Disease (COVID-19). Nadeem MS, Zamzami MA, Choudhry H, Murtaza BN, Kazmi I, Ahmad H, Shakoori AR. Pathogens 9 E307 (2020)
- Two Years into the COVID-19 Pandemic: Lessons Learned. da Silva SJR, do Nascimento JCF, Germano Mendes RP, Guarines KM, Targino Alves da Silva C, da Silva PG, de Magalhães JJF, Vigar JRJ, Silva-Júnior A, Kohl A, Pardee K, Pena L. ACS Infect Dis 8 1758-1814 (2022)
- Thermostability, Tunability, and Tenacity of RNA as Rubbery Anionic Polymeric Materials in Nanotechnology and Nanomedicine-Specific Cancer Targeting with Undetectable Toxicity. Binzel DW, Li X, Burns N, Khan E, Lee WJ, Chen LC, Ellipilli S, Miles W, Ho YS, Guo P. Chem Rev 121 7398-7467 (2021)
- [Human coronaviruses]. Vabret A, Dina J, Brison E, Brouard J, Freymuth F. Pathol Biol (Paris) 57 149-160 (2009)
- Cellular and Humoral Immune Responses in Covid-19 and Immunotherapeutic Approaches. Hasan A, Al-Ozairi E, Al-Baqsumi Z, Ahmad R, Al-Mulla F. Immunotargets Ther 10 63-85 (2021)
- A Review of Human Coronaviruses' Receptors: The Host-Cell Targets for the Crown Bearing Viruses. Nassar A, Ibrahim IM, Amin FG, Magdy M, Elgharib AM, Azzam EB, Nasser F, Yousry K, Shamkh IM, Mahdy SM, Elfiky AA. Molecules 26 6455 (2021)
- Coronavirus (SARS-CoV-2) Pandemic: Future Challenges for Dental Practitioners. Bordea IR, Xhajanka E, Candrea S, Bran S, Onișor F, Inchingolo AD, Malcangi G, Pham VH, Inchingolo AM, Scarano A, Lorusso F, Isacco CG, Aityan SK, Ballini A, Dipalma G, Inchingolo F. Microorganisms 8 E1704 (2020)
- A Recent Update on Advanced Molecular Diagnostic Techniques for COVID-19 Pandemic: An Overview. Roberts A, Chouhan RS, Shahdeo D, Shrikrishna NS, Kesarwani V, Horvat M, Gandhi S. Front Immunol 12 732756 (2021)
- Human gene polymorphisms and their possible impact on the clinical outcome of SARS-CoV-2 infection. Hashemi SMA, Thijssen M, Hosseini SY, Tabarraei A, Pourkarim MR, Sarvari J. Arch Virol 166 2089-2108 (2021)
- Multifunctional angiotensin converting enzyme 2, the SARS-CoV-2 entry receptor, and critical appraisal of its role in acute lung injury. Oz M, Lorke DE. Biomed Pharmacother 136 111193 (2021)
- Role and mechanism of angiotensin-converting enzyme 2 in acute lung injury in coronavirus disease 2019. Liu MY, Zheng B, Zhang Y, Li JP. Chronic Dis Transl Med 6 98-105 (2020)
- SARS-CoV-2 variants evolved during the early stage of the pandemic and effects of mutations on adaptation in Wuhan populations. Awadasseid A, Wu Y, Tanaka Y, Zhang W. Int J Biol Sci 17 97-106 (2021)
- Why COVID-19 Transmission Is More Efficient and Aggressive Than Viral Transmission in Previous Coronavirus Epidemics? Elrashdy F, Redwan EM, Uversky VN. Biomolecules 10 E1312 (2020)
- A lesson from a saboteur: High-MW kininogen impact in coronavirus-induced disease 2019. Colarusso C, Terlizzi M, Pinto A, Sorrentino R. Br J Pharmacol 177 4866-4872 (2020)
- Molecular Characteristics, Functions, and Related Pathogenicity of MERS-CoV Proteins. Li YH, Hu CY, Wu NP, Yao HP, Li LJ. Engineering (Beijing) 5 940-947 (2019)
- PEDV: Insights and Advances into Types, Function, Structure, and Receptor Recognition. Lin F, Zhang H, Li L, Yang Y, Zou X, Chen J, Tang X. Viruses 14 1744 (2022)
- The variants of SARS-CoV-2 and the challenges of vaccines. Han X, Ye Q. J Med Virol 94 1366-1372 (2022)
- Betacoronavirus Genomes: How Genomic Information has been Used to Deal with Past Outbreaks and the COVID-19 Pandemic. Llanes A, Restrepo CM, Caballero Z, Rajeev S, Kennedy MA, Lleonart R. Int J Mol Sci 21 E4546 (2020)
- COVID-19 and Heart: From Clinical Features to Pharmacological Implications. Russo V, Bottino R, Carbone A, Rago A, Papa AA, Golino P, Nigro G. J Clin Med 9 E1944 (2020)
- Immunogenetic Predictors of Severe COVID-19. Malkova A, Kudlay D, Kudryavtsev I, Starshinova A, Yablonskiy P, Shoenfeld Y. Vaccines (Basel) 9 211 (2021)
- SARS-CoV-2 Entry Related Viral and Host Genetic Variations: Implications on COVID-19 Severity, Immune Escape, and Infectivity. Huang SW, Wang SF. Int J Mol Sci 22 3060 (2021)
- Genomic Analysis of the Emergence, Evolution, and Spread of Human Respiratory RNA Viruses. Lam TT, Zhu H, Guan Y, Holmes EC. Annu Rev Genomics Hum Genet 17 193-218 (2016)
- Integrins: An Important Link between Angiogenesis, Inflammation and Eye Diseases. Mrugacz M, Bryl A, Falkowski M, Zorena K. Cells 10 1703 (2021)
- Receptor-binding domains of spike proteins of emerging or re-emerging viruses as targets for development of antiviral vaccines. Jiang S, Lu L, Liu Q, Xu W, Du L. Emerg Microbes Infect 1 e13 (2012)
- Towards our understanding of SARS-CoV, an emerging and devastating but quickly conquered virus. Feng Y, Gao GF. Comp Immunol Microbiol Infect Dis 30 309-327 (2007)
- The recent outbreaks of human coronaviruses: A medicinal chemistry perspective. Pillaiyar T, Wendt LL, Manickam M, Easwaran M. Med Res Rev 41 72-135 (2021)
- ACE2 partially dictates the host range and tropism of SARS-CoV-2. Gao S, Zhang L. Comput Struct Biotechnol J 18 4040-4047 (2020)
- Pathogenesis and management of myocardial injury in coronavirus disease 2019. Wei ZY, Geng YJ, Huang J, Qian HY. Eur J Heart Fail 22 1994-2006 (2020)
- Phylogenetic perspectives on the epidemiology and origins of SARS and SARS-like coronaviruses. Yip CW, Hon CC, Shi M, Lam TT, Chow KY, Zeng F, Leung FC. Infect Genet Evol 9 1185-1196 (2009)
- Potential of SARS-CoV-2 to Cause CNS Infection: Biologic Fundamental and Clinical Experience. Huang J, Zheng M, Tang X, Chen Y, Tong A, Zhou L. Front Neurol 11 659 (2020)
- Vaccines and Therapies in Development for SARS-CoV-2 Infections. Wu D, Koganti R, Lambe UP, Yadavalli T, Nandi SS, Shukla D. J Clin Med 9 E1885 (2020)
- Angiotensin-converting enzyme 2: The old door for new severe acute respiratory syndrome coronavirus 2 infection. Tan HW, Xu YM, Lau ATY. Rev Med Virol 30 e2122 (2020)
- Human coronaviruses: Origin, host and receptor. Tang G, Liu Z, Chen D. J Clin Virol 155 105246 (2022)
- Immunopathogenesis of Coronavirus-Induced Acute Respiratory Distress Syndrome (ARDS): Potential Infection-Associated Hemophagocytic Lymphohistiocytosis. Quan C, Li C, Ma H, Li Y, Zhang H. Clin Microbiol Rev 34 e00074-20 (2020)
- Outbreak of SARS-CoV2: Pathogenesis of infection and cardiovascular involvement. Amirfakhryan H, Safari F. Hellenic J Cardiol 62 13-23 (2021)
- Precision therapeutic targets for COVID-19. Krumm ZA, Lloyd GM, Francis CP, Nasif LH, Mitchell DA, Golde TE, Giasson BI, Xia Y. Virol J 18 66 (2021)
- The Transmission of SARS-CoV-2 Infection on the Ocular Surface and Prevention Strategies. Kitazawa K, Deinhardt-Emmer S, Inomata T, Deshpande S, Sotozono C. Cells 10 796 (2021)
- An Overview of the Crystallized Structures of the SARS-CoV-2. Ionescu MI. Protein J 39 600-618 (2020)
- Common Inflammatory Mechanisms in COVID-19 and Parkinson's Diseases: The Role of Microbiome, Pharmabiotics and Postbiotics in Their Prevention. Danilenko V, Devyatkin A, Marsova M, Shibilova M, Ilyasov R, Shmyrev V. J Inflamm Res 14 6349-6381 (2021)
- Exercise Training and Cardiac Rehabilitation in COVID-19 Patients with Cardiovascular Complications: State of Art. Calabrese M, Garofano M, Palumbo R, Di Pietro P, Izzo C, Damato A, Venturini E, Iesu S, Virtuoso N, Strianese A, Ciccarelli M, Galasso G, Vecchione C. Life (Basel) 11 259 (2021)
- Implications of testicular ACE2 and the renin-angiotensin system for SARS-CoV-2 on testis function. Edenfield RC, Easley CA. Nat Rev Urol 19 116-127 (2022)
- COVID-19 infection and liver injury: Clinical features, biomarkers, potential mechanisms, treatment, and management challenges. Sivandzadeh GR, Askari H, Safarpour AR, Ejtehadi F, Raeis-Abdollahi E, Vaez Lari A, Abazari MF, Tarkesh F, Bagheri Lankarani K. World J Clin Cases 9 6178-6200 (2021)
- Cardiovascular disease in patients with COVID-19: evidence from cardiovascular pathology to treatment. Luo J, Zhu X, Jian J, Chen X, Yin K. Acta Biochim Biophys Sin (Shanghai) 53 273-282 (2021)
- Coronavirus-Induced Host Cubic Membranes and Lipid-Related Antiviral Therapies: A Focus on Bioactive Plasmalogens. Deng Y, Angelova A. Front Cell Dev Biol 9 630242 (2021)
- Engineering a Model to Study Viral Infections: Bioprinting, Microfluidics, and Organoids to Defeat Coronavirus Disease 2019 (COVID-19). Shpichka A, Bikmulina P, Peshkova M, Kosheleva N, Zurina I, Zahmatkesh E, Khoshdel-Rad N, Lipina M, Golubeva E, Butnaru D, Svistunov A, Vosough M, Timashev P. Int J Bioprint 6 302 (2020)
- From Alpha to Omicron: How Different Variants of Concern of the SARS-Coronavirus-2 Impacted the World. Andre M, Lau LS, Pokharel MD, Ramelow J, Owens F, Souchak J, Akkaoui J, Ales E, Brown H, Shil R, Nazaire V, Manevski M, Paul NP, Esteban-Lopez M, Ceyhan Y, El-Hage N. Biology (Basel) 12 1267 (2023)
- Is highly expressed ACE 2 in pregnant women "a curse" in times of COVID-19 pandemic? Dhaundiyal A, Kumari P, Jawalekar SS, Chauhan G, Kalra S, Navik U. Life Sci 264 118676 (2021)
- Protective neutralizing epitopes in SARS-CoV-2. Liu H, Wilson IA. Immunol Rev 310 76-92 (2022)
- SARS-CoV-2/Renin-Angiotensin System: Deciphering the Clues for a Couple with Potentially Harmful Effects on Skeletal Muscle. Gonzalez A, Orozco-Aguilar J, Achiardi O, Simon F, Cabello-Verrugio C. Int J Mol Sci 21 E7904 (2020)
- Structural proteomics of the SARS coronavirus: a model response to emerging infectious diseases. Bartlam M, Xu Y, Rao Z. J Struct Funct Genomics 8 85-97 (2007)
- Studies of severe acute respiratory syndrome coronavirus pathology in human cases and animal models. Nagata N, Iwata-Yoshikawa N, Taguchi F. Vet Pathol 47 881-892 (2010)
- The Role of Smoking and Nicotine in the Transmission and Pathogenesis of COVID-19. Sifat AE, Nozohouri S, Villalba H, Vaidya B, Abbruscato TJ. J Pharmacol Exp Ther 375 498-509 (2020)
- Genetically modified mouse models to help fight COVID-19. Gurumurthy CB, Quadros RM, Richardson GP, Poluektova LY, Mansour SL, Ohtsuka M. Nat Protoc 15 3777-3787 (2020)
- Novel insights into the treatment of SARS-CoV-2 infection: An overview of current clinical trials. Oroojalian F, Haghbin A, Baradaran B, Hemmat N, Shahbazi MA, Baghi HB, Mokhtarzadeh A, Hamblin MR. Int J Biol Macromol 165 18-43 (2020)
- Spiking dependence of SARS-CoV-2 pathogenicity on TMPRSS2. Abbasi AZ, Kiyani DA, Hamid SM, Saalim M, Fahim A, Jalal N. J Med Virol 93 4205-4218 (2021)
- The Contribution of Endothelial Dysfunction in Systemic Injury Subsequent to SARS-Cov-2 Infection. Maiuolo J, Mollace R, Gliozzi M, Musolino V, Carresi C, Paone S, Scicchitano M, Macrì R, Nucera S, Bosco F, Scarano F, Zito MC, Ruga S, Tavernese A, Mollace V. Int J Mol Sci 21 E9309 (2020)
- The Potential Role of Extracellular Vesicles in COVID-19 Treatment: Opportunity and Challenge. Yan YY, Zhou WM, Wang YQ, Guo QR, Zhao FX, Zhu ZY, Xing YX, Zhang HY, Aljofan M, Jarrahi AM, Makabel B, Zhang JY. Front Mol Biosci 8 699929 (2021)
- The Repurposed ACE2 Inhibitors: SARS-CoV-2 Entry Blockers of Covid-19. Ahmad I, Pawara R, Surana S, Patel H. Top Curr Chem (Cham) 379 40 (2021)
- Viral, host and environmental factors that favor anthropozoonotic spillover of coronaviruses: An opinionated review, focusing on SARS-CoV, MERS-CoV and SARS-CoV-2. da Silva PG, Mesquita JR, de São José Nascimento M, Ferreira VAM. Sci Total Environ 750 141483 (2021)
- Role of SARS-CoV-2 and ACE2 variations in COVID-19. Antony P, Vijayan R. Biomed J 44 235-244 (2021)
- Roles of host mitochondria in the development of COVID-19 pathology: Could mitochondria be a potential therapeutic target? Srinivasan K, Pandey AK, Livingston A, Venkatesh S. Mol Biomed 2 38 (2021)
- Severe acute respiratory syndrome coronavirus entry into host cells: Opportunities for therapeutic intervention. Yeung KS, Yamanaka GA, Meanwell NA. Med Res Rev 26 414-433 (2006)
- The role of immune activation and antigen persistence in acute and long COVID. Opsteen S, Files JK, Fram T, Erdmann N. J Investig Med 71 545-562 (2023)
- Update of the current knowledge on genetics, evolution, immunopathogenesis, and transmission for coronavirus disease 19 (COVID-19). Tizaoui K, Zidi I, Lee KH, Ghayda RA, Hong SH, Li H, Smith L, Koyanagi A, Jacob L, Kronbichler A, Shin JI. Int J Biol Sci 16 2906-2923 (2020)
- Demystifying mRNA vaccines: an emerging platform at the forefront of cryptic diseases. Rouf NZ, Biswas S, Tarannum N, Oishee LM, Muna MM. RNA Biol 19 386-410 (2022)
- Host Defence RNases as Antiviral Agents against Enveloped Single Stranded RNA Viruses. Li J, Boix E. Virulence 12 444-469 (2021)
- Mechanistic insights of host cell fusion of SARS-CoV-1 and SARS-CoV-2 from atomic resolution structure and membrane dynamics. Chakraborty H, Bhattacharjya S. Biophys Chem 265 106438 (2020)
- Nanotheranostics against COVID-19: From multivalent to immune-targeted materials. Hassanzadeh P. J Control Release 328 112-126 (2020)
- SARS-CoV-2, Early Entry Events. Chambers JP, Yu J, Valdes JJ, Arulanandam BP. J Pathog 2020 9238696 (2020)
- Spike protein mediated membrane fusion during SARS-CoV-2 infection. Li X, Yuan H, Li X, Wang H. J Med Virol 95 e28212 (2023)
- An overview of human proteins and genes involved in SARS-CoV-2 infection. Jahanafrooz Z, Chen Z, Bao J, Li H, Lipworth L, Guo X. Gene 808 145963 (2022)
- Biological characteristics and biomarkers of novel SARS-CoV-2 facilitated rapid development and implementation of diagnostic tools and surveillance measures. Ghodake GS, Shinde SK, Kadam AA, Saratale RG, Saratale GD, Syed A, Elgorban AM, Marraiki N, Kim DY. Biosens Bioelectron 177 112969 (2021)
- Complement and coagulation: key triggers of COVID-19-induced multiorgan pathology. Ghebrehiwet B, Peerschke EI. J Clin Invest 130 5674-5676 (2020)
- Recent advances in nanotechnology-based COVID-19 vaccines and therapeutic antibodies. Du L, Yang Y, Zhang X, Li F. Nanoscale 14 1054-1074 (2022)
- Angiotensin-converting enzyme 2: a double-edged sword in COVID-19 patients with an increased risk of heart failure. Razeghian-Jahromi I, Zibaeenezhad MJ, Lu Z, Zahra E, Mahboobeh R, Lionetti V. Heart Fail Rev 26 371-380 (2021)
- Aptamers for Anti-Viral Therapeutics and Diagnostics. Kim TH, Lee SW. Int J Mol Sci 22 4168 (2021)
- Hosting the severe acute respiratory syndrome coronavirus: specific cell factors required for infection. de Haan CA, Rottier PJ. Cell Microbiol 8 1211-1218 (2006)
- Mutations in SARS-CoV-2: Insights on structure, variants, vaccines, and biomedical interventions. Abulsoud AI, El-Husseiny HM, El-Husseiny AA, El-Mahdy HA, Ismail A, Elkhawaga SY, Khidr EG, Fathi D, Mady EA, Najda A, Algahtani M, Theyab A, Alsharif KF, Albrakati A, Bayram R, Abdel-Daim MM, Doghish AS. Biomed Pharmacother 157 113977 (2023)
- Protective Immunity against SARS Subunit Vaccine Candidates Based on Spike Protein: Lessons for Coronavirus Vaccine Development. Khalaj-Hedayati A. J Immunol Res 2020 7201752 (2020)
- A gendered magnifying glass on COVID-19. Salvati L, Biagioni B, Vivarelli E, Parronchi P. Clin Mol Allergy 18 14 (2020)
- An overview of basic molecular biology of SARS-CoV-2 and current COVID-19 prevention strategies. Das A, Ahmed R, Akhtar S, Begum K, Banu S. Gene Rep 23 101122 (2021)
- Current Findings Regarding Natural Components With Potential Anti-2019-nCoV Activity. Zhou J, Huang J. Front Cell Dev Biol 8 589 (2020)
- Diversity of Coronaviruses with Particular Attention to the Interspecies Transmission of SARS-CoV-2. Shehata AA, Attia YA, Rahman MT, Basiouni S, El-Seedi HR, Azhar EI, Khafaga AF, Hafez HM. Animals (Basel) 12 378 (2022)
- Human genetic basis of coronavirus disease 2019. Deng H, Yan X, Yuan L. Signal Transduct Target Ther 6 344 (2021)
- Unraveling virus relationships by structure-based phylogenetic classification. Ng WM, Stelfox AJ, Bowden TA. Virus Evol 6 veaa003 (2020)
- Broad-Spectrum Anti-coronavirus Vaccines and Therapeutics to Combat the Current COVID-19 Pandemic and Future Coronavirus Disease Outbreaks. Cao M, Su X, Jiang S. Stem Cell Reports 16 398-411 (2021)
- COVID-19 infection and nanomedicine applications for development of vaccines and therapeutics: An overview and future perspectives based on polymersomes. Al-Hatamleh MAI, Hatmal MM, Alshaer W, Rahman ENSEA, Mohd-Zahid MH, Alhaj-Qasem DM, Yean CY, Alias IZ, Jaafar J, Ferji K, Six JL, Uskoković V, Yabu H, Mohamud R. Eur J Pharmacol 896 173930 (2021)
- Green chemistry and coronavirus. Ahmadi S, Rabiee N, Fatahi Y, Hooshmand SE, Bagherzadeh M, Rabiee M, Jajarmi V, Dinarvand R, Habibzadeh S, Saeb MR, Varma RS, Shokouhimehr M, Hamblin MR. Sustain Chem Pharm 21 100415 (2021)
- Impact of SARS-CoV-2 on Male Reproductive Health: A Review of the Literature on Male Reproductive Involvement in COVID-19. He W, Liu X, Feng L, Xiong S, Li Y, Chen L, Li Y, Wang G, Li D, Fu B. Front Med (Lausanne) 7 594364 (2020)
- Lung fibrosis: Post-COVID-19 complications and evidences. Hirawat R, Jain N, Aslam Saifi M, Rachamalla M, Godugu C. Int Immunopharmacol 116 109418 (2023)
- Phytopharmaceuticals mediated Furin and TMPRSS2 receptor blocking: can it be a potential therapeutic option for Covid-19? Palit P, Chattopadhyay D, Thomas S, Kundu A, Kim HS, Rezaei N. Phytomedicine 85 153396 (2021)
- SARS-CoV-2 variants preferentially emerge at intrinsically disordered protein sites helping immune evasion. Quaglia F, Salladini E, Carraro M, Minervini G, Tosatto SCE, Le Mercier P. FEBS J 289 4240-4250 (2022)
- Targeting Neurological Manifestations of Coronaviruses by Candidate Phytochemicals: A Mechanistic Approach. Fakhri S, Piri S, Majnooni MB, Farzaei MH, Echeverría J. Front Pharmacol 11 621099 (2020)
- The origins of COVID-19 pandemic: A brief overview. Hao YJ, Wang YL, Wang MY, Zhou L, Shi JY, Cao JM, Wang DP. Transbound Emerg Dis 69 3181-3197 (2022)
- Unraveling the Epidemiology, Geographical Distribution, and Genomic Evolution of Potentially Lethal Coronaviruses (SARS, MERS, and SARS CoV-2). Masood N, Malik SS, Raja MN, Mubarik S, Yu C. Front Cell Infect Microbiol 10 499 (2020)
- Advances in mRNA and other vaccines against MERS-CoV. Tai W, Zhang X, Yang Y, Zhu J, Du L. Transl Res 242 20-37 (2022)
- COVID-19 and diabetes; Possible role of polymorphism and rise of telemedicine. Sayed S. Prim Care Diabetes 15 4-9 (2021)
- Coronaviruses pandemics: Can neutralizing antibodies help? Tong PB, Lin LY, Tran TH. Life Sci 255 117836 (2020)
- Development of variant-proof severe acute respiratory syndrome coronavirus 2, pan-sarbecovirus, and pan-β-coronavirus vaccines. Zhou J, Liu Z, Zhang G, Xu W, Xing L, Lu L, Wang Q, Jiang S. J Med Virol 95 e28172 (2023)
- Insights from the association of SARS-CoV S-protein with its receptor, ACE2. Li W, Choe H, Farzan M. Adv Exp Med Biol 581 209-218 (2006)
- Mitigating Coronavirus Induced Dysfunctional Immunity for At-Risk Populations in COVID-19: Trained Immunity, BCG and "New Old Friends". Kleen TO, Galdon AA, MacDonald AS, Dalgleish AG. Front Immunol 11 2059 (2020)
- Na+/K+-ATPase as a Target of Cardiac Glycosides for the Treatment of SARS-CoV-2 Infection. Souza E Souza KFC, Moraes BPT, Paixão ICNP, Burth P, Silva AR, Gonçalves-de-Albuquerque CF. Front Pharmacol 12 624704 (2021)
- Role of NRF2 and Sirtuin activators in COVID-19. Khan H, Patel S, Majumdar A. Clin Immunol 233 108879 (2021)
- Targeting arachidonic acid-related metabolites in COVID-19 patients: potential use of drug-loaded nanoparticles. Shoieb SM, El-Ghiaty MA, El-Kadi AOS. Emergent Mater 4 265-277 (2021)
- Evolution, Ecology, and Zoonotic Transmission of Betacoronaviruses: A Review. Jelinek HF, Mousa M, Alefishat E, Osman W, Spence I, Bu D, Feng SF, Byrd J, Magni PA, Sahibzada S, Tay GK, Alsafar HS. Front Vet Sci 8 644414 (2021)
- Severe childhood respiratory viral infections. Hon KL, Leung AK. Adv Pediatr 56 47-73 (2009)
- Unraveling the Role of ACE2, the Binding Receptor for SARS-CoV-2, in Inflammatory Bowel Disease. Ferreira-Duarte M, Estevinho MM, Duarte-Araújo M, Magro F, Morato M. Inflamm Bowel Dis 26 1787-1795 (2020)
- A perspective on potential target proteins of COVID-19: Comparison with SARS-CoV for designing new small molecules. Kumar D, Chauhan G, Kalra S, Kumar B, Gill MS. Bioorg Chem 104 104326 (2020)
- ABO Blood System and COVID-19 Susceptibility: Anti-A and Anti-B Antibodies Are the Key Points. Tamayo-Velasco Á, Peñarrubia-Ponce MJ, Álvarez FJ, de la Fuente I, Pérez-González S, Andaluz-Ojeda D. Front Med (Lausanne) 9 882477 (2022)
- Anti-SARS-CoV-1 and -2 nanobody engineering towards avidity-inspired therapeutics. Obeng EM, Dzuvor CKO, Danquah MK. Nano Today 42 101350 (2022)
- Genetic and epigenetic control of ACE2 expression and its possible role in COVID-19. Lima RS, Rocha LPC, Moreira PR. Cell Biochem Funct 39 713-726 (2021)
- Next-generation computational tools and resources for coronavirus research: From detection to vaccine discovery. Kangabam R, Sahoo S, Ghosh A, Roy R, Silla Y, Misra N, Suar M. Comput Biol Med 128 104158 (2021)
- Recent advance of ACE2 and microbiota dysfunction in COVID-19 pathogenesis. Yu Z, Yang Z, Wang Y, Zhou F, Li S, Li C, Li L, Zhang W, Li X. Heliyon 7 e07548 (2021)
- The soluble catalytic ectodomain of ACE2 a biomarker of cardiac remodelling: new insights for heart failure and COVID19. García-Escobar A, Jiménez-Valero S, Galeote G, Jurado-Román A, García-Rodríguez J, Moreno R. Heart Fail Rev 26 961-971 (2021)
- Druggable targets from coronaviruses for designing new antiviral drugs. Silva LR, da Silva Santos-Júnior PF, de Andrade Brandão J, Anderson L, Bassi ÊJ, Xavier de Araújo-Júnior J, Cardoso SH, da Silva-Júnior EF. Bioorg Med Chem 28 115745 (2020)
- Interspecies Jumping of Bat Coronaviruses. Wong ACP, Lau SKP, Woo PCY. Viruses 13 2188 (2021)
- Known Cellular and Receptor Interactions of Animal and Human Coronaviruses: A Review. Everest H, Stevenson-Leggett P, Bailey D, Bickerton E, Keep S. Viruses 14 351 (2022)
- Korean Red Ginseng, a regulator of NLRP3 inflammasome, in the COVID-19 pandemic. Jung EM, Lee GS. J Ginseng Res 46 331-336 (2022)
- Molecular pathogenesis of severe acute respiratory syndrome. Wang H, Rao S, Jiang C. Microbes Infect 9 119-126 (2007)
- SARS-CoV-2: Insights into its structural intricacies and functional aspects for drug and vaccine development. Kaur M, Sharma A, Kumar S, Singh G, Barnwal RP. Int J Biol Macromol 179 45-60 (2021)
- Specificity switching in virus-receptor complexes. Stehle T, Casasnovas JM. Curr Opin Struct Biol 19 181-188 (2009)
- Targeting the intestinal TMPRSS2 protease to prevent SARS-CoV-2 entry into enterocytes-prospects and challenges. Mahmoud IS, Jarrar YB. Mol Biol Rep 48 4667-4675 (2021)
- The Two-Way Switch Role of ACE2 in the Treatment of Novel Coronavirus Pneumonia and Underlying Comorbidities. Pang XC, Zhang HX, Zhang Z, Rinkiko S, Cui YM, Zhu YZ. Molecules 26 E142 (2020)
- A comprehensive review of COVID-19 biology, diagnostics, therapeutics, and disease impacting the central nervous system. Williams A, Branscome H, Khatkar P, Mensah GA, Al Sharif S, Pinto DO, DeMarino C, Kashanchi F. J Neurovirol 27 667-690 (2021)
- Angiotensin-converting enzyme 2 as a potential therapeutic target for COVID-19: A review. Singh B, Singh D, Verma V, Yadav R, Kumar R. J Pharm Anal 12 215-220 (2022)
- COVID-19: inflammatory responses, structure-based drug design and potential therapeutics. Tripathi N, Tripathi N, Goshisht MK. Mol Divers 26 629-645 (2022)
- Experimental Animal Models of Coronavirus Infections: Strengths and Limitations. Casel MAB, Rollon RG, Choi YK. Immune Netw 21 e12 (2021)
- Human monoclonal antibodies as candidate therapeutics against emerging viruses and HIV-1. Zhu Z, Prabakaran P, Chen W, Broder CC, Gong R, Dimitrov DS. Virol Sin 28 71-80 (2013)
- Hypoxemia in COVID-19 patients: An hypothesis. Fisher HK. Med Hypotheses 143 110022 (2020)
- Interactions of renin-angiotensin system and COVID-19: the importance of daily rhythms in ACE2, ADAM17 and TMPRSS2 expression. Zlacká J, Stebelová K, Zeman M, Herichová I. Physiol Res 70 S177-S194 (2021)
- Mechanisms Underlying Potential Therapeutic Approaches for COVID-19. Benani A, Ben Mkaddem S. Front Immunol 11 1841 (2020)
- Protein-Based Nanoparticle Vaccines for SARS-CoV-2. Sung HD, Kim N, Lee Y, Lee EJ. Int J Mol Sci 22 13445 (2021)
- SARS-CoV-2 infection and smoking: What is the association? A brief review. Gupta I, Sohail MU, Elzawawi KE, Amarah AH, Vranic S, Al-Asmakh M, Al Moustafa AE. Comput Struct Biotechnol J 19 1654-1660 (2021)
- SARS-CoV-2-Encoded Proteome and Human Genetics: From Interaction-Based to Ribosomal Biology Impact on Disease and Risk Processes. Sirpilla O, Bauss J, Gupta R, Underwood A, Qutob D, Freeland T, Bupp C, Carcillo J, Hartog N, Rajasekaran S, Prokop JW. J Proteome Res 19 4275-4290 (2020)
- Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV). Tong TR. Perspect Med Virol 16 43-95 (2006)
- Viral metagenomics, protein structure, and reverse genetics: Key strategies for investigating coronaviruses. Johnson BA, Graham RL, Menachery VD. Virology 517 30-37 (2018)
- A Multidisciplinary Approach to Coronavirus Disease (COVID-19). Gediz Erturk A, Sahin A, Bati Ay E, Pelit E, Bagdatli E, Kulu I, Gul M, Mesci S, Eryilmaz S, Oba Ilter S, Yildirim T. Molecules 26 3526 (2021)
- Covid-19 pathogenesis in prostatic cancer and TMPRSS2-ERG regulatory genetic pathway. Afshari A, Janfeshan S, Yaghobi R, Roozbeh J, Azarpira N. Infect Genet Evol 88 104669 (2021)
- Development of antibody resistance in emerging mutant strains of SARS CoV-2: Impediment for COVID-19 vaccines. Beeraka NM, Sukocheva OA, Lukina E, Liu J, Fan R. Rev Med Virol 32 e2346 (2022)
- Neurological manifestations and comorbidity associated with COVID-19: an overview. Kumar M, Thakur AK. Neurol Sci 41 3409-3418 (2020)
- Pharmacogenetics and Precision Medicine Approaches for the Improvement of COVID-19 Therapies. Biswas M, Sawajan N, Rungrotmongkol T, Sanachai K, Ershadian M, Sukasem C. Front Pharmacol 13 835136 (2022)
- Physiological and Immunological Causes of the Susceptibility of Chronic Inflammatory Patients to COVID-19 Infection: Focus on Diabetes. Rahmani-Kukia N, Abbasi A. Front Endocrinol (Lausanne) 12 576412 (2021)
- Predisposing factors of important invasive fungal coinfections in COVID-19 patients: a review article. Zia M, Goli M. J Int Med Res 49 3000605211043413 (2021)
- SARS-CoV-2: phylogenetic origins, pathogenesis, modes of transmission, and the potential role of nanotechnology. Sahu AK, Sreepadmanabh M, Rai M, Chande A. Virusdisease 32 1-12 (2021)
- The nervous system during COVID-19: Caught in the crossfire. Natale NR, Lukens JR, Petri WA. Immunol Rev 311 90-111 (2022)
- Therapeutically effective covalent spike protein inhibitors in treatment of SARS-CoV-2. Choudhary V, Gupta A, Sharma R, Parmar HS. J Proteins Proteom 12 257-270 (2021)
- Thrombosis and Coagulopathy in COVID-19: Current Understanding and Implications for Antithrombotic Treatment in Patients Treated With Percutaneous Coronary Intervention. Liu H, Wang Z, Sun H, Teng T, Li Y, Zhou X, Yang Q. Front Cardiovasc Med 7 599334 (2020)
- Cardiovascular Disease and Coronavirus Disease 2019: Epidemiology, Management, and Prevention. Ishigami J, Kou M, Ding N, Matsushita K. Curr Epidemiol Rep 8 1-8 (2021)
- Cell Entry of Animal Coronaviruses. Cheng YR, Li X, Zhao X, Lin H. Viruses 13 1977 (2021)
- Emergence of deadly severe acute respiratory syndrome coronavirus-2 during 2019-2020. Islam A, Ahmed A, Naqvi IH, Parveen S. Virusdisease 31 128-136 (2020)
- Epigenetic Mechanisms Underlying COVID-19 Pathogenesis. Kaneko S, Takasawa K, Asada K, Shinkai N, Bolatkan A, Yamada M, Takahashi S, Machino H, Kobayashi K, Komatsu M, Hamamoto R. Biomedicines 9 1142 (2021)
- Global landscape of patents related to human coronaviruses. Liu K, Gu Z, Islam MS, Scherngell T, Kong X, Zhao J, Chen X, Hu Y. Int J Biol Sci 17 1588-1599 (2021)
- How Antibodies Recognize Pathogenic Viruses: Structural Correlates of Antibody Neutralization of HIV-1, SARS-CoV-2, and Zika. Abernathy ME, Dam KA, Esswein SR, Jette CA, Bjorkman PJ. Viruses 13 2106 (2021)
- Liver Injury in Patients with Coronavirus Disease 2019 (COVID-19)-A Narrative Review. Łykowska-Szuber L, Wołodźko K, Rychter AM, Szymczak-Tomczak A, Krela-Kaźmierczak I, Dobrowolska A. J Clin Med 10 5048 (2021)
- MicroRNAs as Potential Tools for Predicting Cancer Patients' Susceptibility to SARS-CoV-2 Infection and Vaccination Response. Dias TR, Dias F, Teixeira AL, Sousa H, Oliveira J, Medeiros R. Cells 11 2279 (2022)
- Peptides and peptidomimetics as therapeutic agents for Covid-19. Dahal A, Sonju JJ, Kousoulas KG, Jois SD. Pept Sci (Hoboken) 114 e24245 (2022)
- Research progress of biosensors for detection of SARS-CoV-2 variants based on ACE2. Wei H, Zhang C, Du X, Zhang Z. Talanta 251 123813 (2023)
- Reviews on Biological Activity, Clinical Trial and Synthesis Progress of Small Molecules for the Treatment of COVID-19. Li D, Hu J, Li D, Yang W, Yin SF, Qiu R. Top Curr Chem (Cham) 379 4 (2021)
- Targeted therapy in Coronavirus disease 2019 (COVID-19): Implication from cell and gene therapy to immunotherapy and vaccine. Shirzad M, Nourigorji M, Sajedi A, Ranjbar M, Rasti F, Sourani Z, Moradi M, Mostafa Mir S, Memar MY. Int Immunopharmacol 111 109161 (2022)
- While We Wait for a Vaccine Against SARS-CoV-2, Why Not Think About Available Drugs? Barrantes FJ. Front Physiol 11 820 (2020)
- In Vitro Models for Studying Entry, Tissue Tropism, and Therapeutic Approaches of Highly Pathogenic Coronaviruses. Najafi Fard S, Petrone L, Petruccioli E, Alonzi T, Matusali G, Colavita F, Castilletti C, Capobianchi MR, Goletti D. Biomed Res Int 2021 8856018 (2021)
- Mechanism and evolution of human ACE2 binding by SARS-CoV-2 spike. Wrobel AG. Curr Opin Struct Biol 81 102619 (2023)
- Nanoparticles for Coronavirus Control. Kianpour M, Akbarian M, Uversky VN. Nanomaterials (Basel) 12 1602 (2022)
- Neurological damages in COVID-19 patients: Mechanisms and preventive interventions. Sarkar S, Karmakar S, Basu M, Ghosh P, Ghosh MK. MedComm (2020) 4 e247 (2023)
- Potential Application of Tea Polyphenols to the Prevention of COVID-19 Infection: Based on the Gut-Lung Axis. Xu L, Ho CT, Liu Y, Wu Z, Zhang X. Front Nutr 9 899842 (2022)
- Potential mechanism of SARS-CoV-2-associated central and peripheral nervous system impairment. Zhang Y, Chen X, Jia L, Zhang Y. Acta Neurol Scand 146 225-236 (2022)
- The Promise of Aggregation-Induced Emission Luminogens for Detecting COVID-19. Liu Z, Meng T, Tang X, Tian R, Guan W. Front Immunol 12 635558 (2021)
- The fight against COVID-19: Striking a balance in the renin-angiotensin system. Dean AQ, Bozza WP, Twomey JD, Luo S, Nalli A, Zhang B. Drug Discov Today 26 2214-2220 (2021)
- Therapeutic Application of Genome Editing Technologies in Viral Diseases. Kim TH, Lee SW. Int J Mol Sci 23 5399 (2022)
- Toward Understanding Molecular Bases for Biological Diversification of Human Coronaviruses: Present Status and Future Perspectives. Koma T, Adachi S, Doi N, Adachi A, Nomaguchi M. Front Microbiol 11 2016 (2020)
- Translating bioactive peptides for COVID-19 therapy. Bhullar KS, Drews SJ, Wu J. Eur J Pharmacol 890 173661 (2021)
- Understanding the Host Innate Immune Responses against SARS-CoV-2 Infection and COVID-19 Pathogenesis. Kang YW, Park S, Lee KJ, Moon D, Kim YM, Lee SW. Immune Netw 21 e1 (2021)
- Animal models for studying coronavirus infections and developing antiviral agents and vaccines. Lin Q, Lu C, Hong Y, Li R, Chen J, Chen W, Chen J. Antiviral Res 203 105345 (2022)
- Anti-COVID-19 drug screening: Frontier concepts and core technologies. Luo H, Zhao M, Tan D, Liu C, Yang L, Qiu L, Gao Y, Yu H. Chin Med 15 115 (2020)
- COVID-19 into Chemical Science Perspective: Chemical Preventive Measures and Drug Development. Adhikari B, Sahu N. ChemistrySelect 6 2010-2028 (2021)
- CRISPR Technology in Gene-Editing-Based Detection and Treatment of SARS-CoV-2. Shademan B, Nourazarian A, Hajazimian S, Isazadeh A, Biray Avci C, Oskouee MA. Front Mol Biosci 8 772788 (2021)
- Emerging zoonotic viruses: new lessons on receptor and entry mechanisms. Gerlier D. Curr Opin Virol 1 27-34 (2011)
- Intrinsic disorder perspective of an interplay between the renin-angiotensin-aldosterone system and SARS-CoV-2. Elrashdy F, Redwan EM, Uversky VN. Infect Genet Evol 85 104510 (2020)
- Mass Spectrometry and Structural Biology Techniques in the Studies on the Coronavirus-Receptor Interaction. Witkowska D. Molecules 25 E4133 (2020)
- Mesenchymal stem cells: a new front emerges in coronavirus disease 2019 treatment. Raza SS, Khan MA. Cytotherapy 24 755-766 (2022)
- Myocardial Injury in COVID-19 and Its Implications in Short- and Long-Term Outcomes. Izquierdo-Marquisá A, Cubero-Gallego H, Aparisi Á, Vaquerizo B, Ribas-Barquet N. Front Cardiovasc Med 9 901245 (2022)
- Severe Acute Respiratory Syndrome Coronavirus-2 Induces Cytokine Storm and Inflammation During Coronavirus Disease 19: Perspectives and Possible Therapeutic Approaches. Mannino F, Bitto A, Irrera N. Front Pharmacol 11 592169 (2020)
- Structural, genomic information and computational analysis of emerging coronavirus (SARS-CoV-2). Agarwal D, Zafar I, Ahmad SU, Kumar S, Ain QU, Sundaray JK, Rather MA. Bull Natl Res Cent 46 170 (2022)
- Structures of the SARS-CoV-2 spike glycoprotein and applications for novel drug development. Liu XH, Cheng T, Liu BY, Chi J, Shu T, Wang T. Front Pharmacol 13 955648 (2022)
- A brief molecular insight of COVID-19: epidemiology, clinical manifestation, molecular mechanism, cellular tropism and immuno-pathogenesis. Singh S, Pandey R, Tomar S, Varshney R, Sharma D, Gangenahalli G. Mol Cell Biochem 476 3987-4002 (2021)
- Advances in Next-Generation Coronavirus Vaccines in Response to Future Virus Evolution. Li L, Wei Y, Yang H, Yan J, Li X, Li Z, Zhao Y, Liang H, Wang H. Vaccines (Basel) 10 2035 (2022)
- COVID-19 and relative angiotensin-converting enzyme 2 deficiency: role in disease severity and therapeutic response. Ryan PM, Caplice N. Open Heart 7 e001302 (2020)
- Genetic Variants within SARS-CoV-2 Human Receptor Genes May Contribute to Variable Disease Outcomes in Different Ethnicities. Adimulam T, Arumugam T, Gokul A, Ramsuran V. Int J Mol Sci 24 8711 (2023)
- Insights into SARS-CoV-2: Medicinal Chemistry Approaches to Combat Its Structural and Functional Biology. Zhuo LS, Wang MS, Yang JF, Xu HC, Huang W, Shang LQ, Yang GF. Top Curr Chem (Cham) 379 23 (2021)
- Interacting Proteins, Polymorphisms and the Susceptibility of Animals to SARS-CoV-2. Hancock JT, Rouse RC, Stone E, Greenhough A. Animals (Basel) 11 797 (2021)
- Multivalent ACE2 engineering-A promising pathway for advanced coronavirus nanomedicine development. Obeng EM, Fianu I, Danquah MK. Nano Today 46 101580 (2022)
- Nanoparticles and Antiviral Vaccines. Liu S, Hu M, Liu X, Liu X, Chen T, Zhu Y, Liang T, Xiao S, Li P, Ma X. Vaccines (Basel) 12 30 (2023)
- Recent progress in the development of potential drugs against SARS-CoV-2. Chen J, Ali F, Khan I, Zhu YZ. Curr Res Pharmacol Drug Discov 2 100057 (2021)
- Severe acute respiratory syndrome-coronavirus-2: Current advances in therapeutic targets and drug development. Suganya S, Divya S, Parani M. Rev Med Virol 31 e2174 (2021)
- Small Resistance Artery Disease and ACE2 in Hypertension: A New Paradigm in the Context of COVID-19. Galán M, Jiménez-Altayó F. Front Cardiovasc Med 7 588692 (2020)
- The highly cited SARS research literature. Kostoff RN. Crit Rev Microbiol 36 299-317 (2010)
- A narrative review on the basic and clinical aspects of the novel SARS-CoV-2, the etiologic agent of COVID-19. Hokello J, Sharma AL, Shukla GC, Tyagi M. Ann Transl Med 8 1686 (2020)
- ACE2 enhance viral infection or viral infection aggravate the underlying diseases. Teng S, Tang Q. Comput Struct Biotechnol J 18 2100-2106 (2020)
- Cardiovascular Considerations in COVID19: A Comprehensive Review. Keihanian F, Bigdelu L. Ther Clin Risk Manag 16 1089-1097 (2020)
- Drug screening and development from the affinity of S protein of new coronavirus with ACE2. Jiang YP, Zhao XX, Lv HQ, Wen CP. Eur J Clin Microbiol Infect Dis 40 715-723 (2021)
- Lung Organoids as Model to Study SARS-CoV-2 Infection. Peng L, Gao L, Wu X, Fan Y, Liu M, Chen J, Song J, Kong J, Dong Y, Li B, Liu A, Bao F. Cells 11 2758 (2022)
- Molecular scaffolds from mother nature as possible lead compounds in drug design and discovery against coronaviruses: A landscape analysis of published literature and molecular docking studies. Khursheed A, Jain V, Rasool A, Rather MA, Malik NA, Shalla AH. Microb Pathog 157 104933 (2021)
- Mysterious Virus: A Review on Behavior and Treatment Approaches of the Novel Coronavirus, 2019-nCoV. Hemmati F, Saedi S, Hemmati-Dinarvand M, Hemmati-Dinarvand M, Zarei M, Seghatoleslam A. Arch Med Res 51 375-383 (2020)
- Pandemic COVID-19 caused by SARS-CoV-2: genetic structure, vaccination, and therapeutic approaches. Marei HE, Althani A, Afifi N, Pozzoli G, Caceci T, Angelini F, Cenciarelli C. Mol Biol Rep 48 6513-6524 (2021)
- The Emergence of SARS-CoV-2 Variants With a Lower Antibody Response: A Genomic and Clinical Perspective. Biswas S, Mahmud S, Mita MA, Afrose S, Hasan MR, Paul GK, Shimu MSS, Uddin MS, Zaman S, Park MN, Siyadatpanah A, Obaidullah AJ, Saleh MA, Simal-Gandara J, Kim B. Front Med (Lausanne) 9 825245 (2022)
- Zoonoses in the Emergence of Human Viral Diseases. Åsjö B, Kruse H. Perspect Med Virol 16 15-41 (2006)
- Aptamers: A prospective tool for infectious diseases diagnosis. Chen J, Zhou J, Peng Y, Xie Y, Xiao Y. J Clin Lab Anal 36 e24725 (2022)
- Comprehensive Literature Review and Evidence evaluation of Experimental Treatment in COVID 19 Contagion. Boregowda U, Gandhi D, Jain N, Khanna K, Gupta N. Clin Med Insights Circ Respir Pulm Med 14 1179548420964140 (2020)
- Emerging Trends of Gold Nanostructures for Point-of-Care Biosensor-Based Detection of COVID-19. Yadav AK, Basavegowda N, Shirin S, Raju S, Sekar R, Somu P, Uthappa UT, Abdi G. Mol Biotechnol (2024)
- Enzymes in the time of COVID-19: An overview about the effects in the human body, enzyme market, and perspectives for new drugs. Fé LXSGM, Cipolatti EP, Pinto MCC, Branco S, Nogueira FCS, Ortiz GMD, Pinheiro AS, Manoel EA. Med Res Rev 42 2126-2167 (2022)
- Exploring the Role of ACE2 as a Connecting Link between COVID-19 and Parkinson's Disease. Angelopoulou E, Karlafti E, Georgakopoulou VE, Papalexis P, Papageorgiou SG, Tegos T, Savopoulos C. Life (Basel) 13 536 (2023)
- From the environment to the cells: An overview on pivotal factors which affect spreading and infection in COVID-19 pandemic. Zarei M, Rahimi K, Hassanzadeh K, Abdi M, Hosseini V, Fathi A, Kakaei K. Environ Res 201 111555 (2021)
- Impact of COVID-19 on Prostate Cancer Management: Guidelines for Urologists. Dovey Z, Mohamed N, Gharib Y, Ratnani P, Hammouda N, Nair SS, Chakravarty D, Sobotka S, Lantz A, Wiklund P, Kyprianou N, Tewari A. Eur Urol Open Sci 20 1-11 (2020)
- Involvement of sialoglycans in SARS-COV-2 infection: Opportunities and challenges for glyco-based inhibitors. Kuhaudomlarp S, Imberty A. IUBMB Life 74 1253-1263 (2022)
- Molecular Insights into the Crosstalk Between Immune Inflammation Nexus and SARS-CoV-2 Virus. Bose P, Sunita P, Pattanayak SP. Curr Microbiol 78 3813-3828 (2021)
- Molecular mechanisms implicated in SARS-CoV-2 liver tropism. Quarleri J, Delpino MV. World J Gastroenterol 28 6875-6887 (2022)
- Pharmacological Treatment for the Management of COVID 19: A Narrative Review. Dhakal N, Poudyal A, Gyanwali P. JNMA J Nepal Med Assoc 59 614-621 (2021)
- Remarkable gastrointestinal and liver manifestations of COVID-19: A clinical and radiologic overview. Fang LG, Zhou Q. World J Clin Cases 9 4969-4979 (2021)
- Role of tyrosine kinase inhibitor in chronic myeloid leukemia patients with SARS-CoV-2 infection: A narrative Review. Asif M, Amir M, Hussain A, Achakzai NM, Natesan Pushparaj P, Rasool M. Medicine (Baltimore) 101 e29660 (2022)
- Status and Developing Strategies for Neutralizing Monoclonal Antibody Therapy in the Omicron Era of COVID-19. Ren Z, Shen C, Peng J. Viruses 15 1297 (2023)
- Stroke Associated with SARS-CoV-2 Infection and its Pathogenesis: A Systematic Review. Kazemi S, Pourgholaminejad A, Saberi A. Basic Clin Neurosci 12 569-586 (2021)
- Structure of SARS-CoV-2 Spike Glycoprotein for Therapeutic and Preventive Target. Hong J, Jhun H, Choi YO, Taitt AS, Bae S, Lee Y, Song CS, Yeom SC, Kim S. Immune Netw 21 e8 (2021)
- Susceptibility of domestic and companion animals to SARS-CoV-2: a comprehensive review. Pourbagher-Shahri AM, Mohammadi G, Ghazavi H, Forouzanfar F. Trop Anim Health Prod 55 60 (2023)
- The Pathogenic Features of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2): Possible Mechanisms for Immune Evasion? Wang Z, Zhou M, Fu Z, Zhao L. Front Immunol 12 693579 (2021)
- The effect of various compounds on the COVID mechanisms, from chemical to molecular aspects. Mahmoudi S, Dehkordi MM, Asgarshamsi MH. Biophys Chem 288 106824 (2022)
- The impact of the COVID-19 pandemic on Clostridioides difficile infection and utilization of fecal microbiota transplantation. Bachour SP, Dalal R, Allegretti JR. Therap Adv Gastroenterol 16 17562848231165581 (2023)
- The role of mediator complex subunit 19 in human diseases. Zhang Y, Qin P, Tian L, Yan J, Zhou Y. Exp Biol Med (Maywood) 246 1681-1687 (2021)
- The significance of bioengineered nanoplatforms against SARS-CoV-2: From detection to genome editing. Hassanzadeh P. Life Sci 274 119289 (2021)
- Use of nanotechnology in combating coronavirus. Gharpure S, Ankamwar B. 3 Biotech 11 358 (2021)
- [How to define the species barrier to pathogen transmission?]. Sansonetti P. Bull Acad Natl Med 190 611-22; discussion 623, 625-7 (2006)
- A Narrative Review of a Pulmonary Aerosolized Formulation or a Nasal Drop Using Sera Containing Neutralizing Antibodies Collected from COVID-19-Recovered Patients as a Probable Therapy for COVID-19. Fatima N, Kaushik V, Ayoub A. Iran J Med Sci 46 151-168 (2021)
- COVID-19 and the Kidney: Should Nephrologists Care about COVID-19 rather than Maintaining Their Focus on Renal Patients? Perico N, Perico L, Ronco C, Remuzzi G. Contrib Nephrol 199 229-243 (2021)
- Characterization of the angiotensin-converting enzyme 2 (ACE2), the main receptor for the SARS-CoV-2 virus. Jami G, Ataee M, Esmaeili V, Chamani S, Rezaei A, Naghizadeh A. Am J Clin Exp Immunol 12 24-44 (2023)
- Managing the COVID-19 Pandemic: Research Strategies Based on the Evolutionary and Molecular Characteristics of Coronaviruses. Majid S, Farooq R, Khan MS, Rashid S, Bhat SA, Wani HA, Qureshi W. SN Compr Clin Med 2 1767-1776 (2020)
- Molecular and Clinical Investigation of COVID-19: From Pathogenesis and Immune Responses to Novel Diagnosis and Treatment. Kashani NR, Azadbakht J, Ehteram H, Kashani HH, Rajabi-Moghadam H, Ahmad E, Nikzad H, Hosseini ES. Front Mol Biosci 9 770775 (2022)
- Overview of pharmacotherapy targeting COVID-19 disease based on ACE-2: current challenges and future directions. Vitiello A, Zovi A, Trama U, Ferrara F. Herz 48 372-375 (2023)
- Research Advances on Swine Acute Diarrhea Syndrome Coronavirus. Liu C, Huang W, He X, Feng Z, Chen Q. Animals (Basel) 14 448 (2024)
- Research progress on coronavirus S proteins and their receptors. Yuan HW, Wen HL. Arch Virol 166 1811-1817 (2021)
- SARS-CoV-2 Omicron: Viral Evolution, Immune Evasion, and Alternative Durable Therapeutic Strategies. Guo H, Ha S, Botten JW, Xu K, Zhang N, An Z, Strohl WR, Shiver JW, Fu TM. Viruses 16 697 (2024)
- SARS-CoV-2 infection: Understanding the immune system abnormalities to get an adequate diagnosis. Medina-Quero K, Barreto-Rodriguez O, Mendez-Rodriguez V, Sanchez-Moncivais A, Buendia-Roldan I, Chavez-Galan L. Bosn J Basic Med Sci 21 503-514 (2021)
- SARS-CoV-2 mechanisms of cell tropism in various organs considering host factors. Behboudi E, Nooreddin Faraji S, Daryabor G, Mohammad Ali Hashemi S, Asadi M, Edalat F, Javad Raee M, Hatam G. Heliyon 10 e26577 (2024)
- SARS-CoV-2 prevalence in domestic and wildlife animals: A genomic and docking based structural comprehensive review. Das T, Sikdar S, Chowdhury MHU, Nyma KJ, Adnan M. Heliyon 9 e19345 (2023)
- Severe acute respiratory syndrome coronavirus 2 variants-Possibility of universal vaccine design: A review. Yoon E, Kim D, Jeon H, Kwon Y, Jang Y, Kim S, Hwang KY. Comput Struct Biotechnol J 20 3533-3544 (2022)
- Susceptibility to Metabolic Diseases in COVID-19: To be or Not to be an Issue. Kaviani M, Keshtkar S, Soleimanian S, Sabet Sarvestani F, Azarpira N, Pakbaz S. Front Mol Biosci 9 803314 (2022)
- A Novel Vision of Reinforcing Nanofibrous Masks with Metal Nanoparticles: Antiviral Mechanisms Investigation. Hadinejad F, Morad H, Jahanshahi M, Zarrabi A, Pazoki-Toroudi H, Mostafavi E. Adv Fiber Mater 1-45 (2023)
- Current trends in diagnosis and treatment strategies of COVID-19 infection. Tiwari V, Kumar M, Tiwari A, Sahoo BM, Singh S, Kumar S, Saharan R. Environ Sci Pollut Res Int 28 64987-65013 (2021)
- Development of Coronavirus Treatments Using Neutralizing Antibodies. Fouladirad S, Bach H. Microorganisms 9 165 (2021)
- Elevated Arterial Blood Pressure as a Delayed Complication Following COVID-19-A Narrative Review. Bielecka E, Sielatycki P, Pietraszko P, Zapora-Kurel A, Zbroch E. Int J Mol Sci 25 1837 (2024)
- Impact of Hypertension and Physical Fitness on SARS-COV-2 and Related Consequences. (Possible Mechanisms with Focusing on ACE2). Kushkestani M, Parvani M, Moghadassi M, Kazemzadeh Y, Moradi K. Caspian J Intern Med 13 148-154 (2022)
- Mesenchymal stem cells in SARS-CoV-2 infection: A hype or hope. Pal D, Goyal J, Sharma U, Sharma A, Prashar S, Rathi G, Sharma B, Kumar U. Life Sci 284 119901 (2021)
- Nanomaterials to combat SARS-CoV-2: Strategies to prevent, diagnose and treat COVID-19. Valenzuela-Fernández A, Cabrera-Rodriguez R, Ciuffreda L, Perez-Yanes S, Estevez-Herrera J, González-Montelongo R, Alcoba-Florez J, Trujillo-González R, García-Martínez de Artola D, Gil-Campesino H, Díez-Gil O, Lorenzo-Salazar JM, Flores C, Garcia-Luis J. Front Bioeng Biotechnol 10 1052436 (2022)
- New-onset and relapsed Graves' disease following COVID-19 vaccination: a comprehensive review of reported cases. Chen K, Gao Y, Li J. Eur J Med Res 28 232 (2023)
- Novel Coronavirus (nCoV): a Bitter Old Enemy in a New Avatar. Singh AB, Singh N. SN Compr Clin Med 2 1083-1088 (2020)
- Role of marine natural products in the development of antiviral agents against SARS-CoV-2: potential and prospects. Nagahawatta DP, Liyanage NM, Jayawardena TU, Jayawardhana HHACK, Jeong SH, Kwon HJ, Jeon YJ. Mar Life Sci Technol 6 280-297 (2024)
- Substances of abuse and their effect on SAR-CoV-2 pathogenesis. Antwi I, Watkins D, Pedawi A, Ghrayeb A, Van de Vuurst C, Cory TJ. NeuroImmune Pharm Ther 2 301-316 (2023)
- The Key Site Variation and Immune Challenges in SARS-CoV-2 Evolution. Liu Y, Ye Q. Vaccines (Basel) 11 1472 (2023)
- The Protective Potential Role of ACE2 against COVID-19. Golab F, Vahabzadeh G, SadeghRoudbari L, Shirazi A, Shabani R, Tanbakooei S, Kooshesh L. Adv Virol 2023 8451931 (2023)
- The immunobiology of SARS-CoV-2 infection and vaccine responses: potential influences of cross-reactive memory responses and aging on efficacy and off-target effects. Collins CP, Longo DL, Murphy WJ. Front Immunol 15 1345499 (2024)
- Treating COVID-19 with Medicinal Plants: Is It Even Conceivable? A Comprehensive Review. Al-Jamal H, Idriss S, Roufayel R, Abi Khattar Z, Fajloun Z, Sabatier JM. Viruses 16 320 (2024)
- Update on treatment and preventive interventions against COVID-19: an overview of potential pharmacological agents and vaccines. Xiao Y, Xu H, Guo W, Zhao Y, Luo Y, Wang M, He Z, Ding Z, Liu J, Deng L, Sha F, Ma X. Mol Biomed 1 16 (2020)
- [Progress and analysis on the development of 2019-nCoV vaccine]. Kang Z, Tang M. Sheng Wu Yi Xue Gong Cheng Xue Za Zhi 37 373-379 (2020)
- [Replication and transmission mechanisms of highly pathogenic human coronavirus]. He Y, Zheng C. Zhejiang Da Xue Xue Bao Yi Xue Ban 49 324-339 (2020)
- ACE2-using merbecoviruses: Further evidence of convergent evolution of ACE2 recognition by NeoCoV and other MERS-CoV related viruses. Xiong Q, Ma C, Liu C, Tong F, Huang M, Yan H. Cell Insight 3 100145 (2024)
- Current development of severe acute respiratory syndrome coronavirus 2 neutralizing antibodies (Review). Zhang T, Yang D, Tang L, Hu Y. Mol Med Rep 30 148 (2024)
- Diabetes as one of the long-term COVID-19 complications: from the potential reason of more diabetic patients' susceptibility to COVID-19 to the possible caution of future global diabetes tsunami. Sharbatdar Y, Mousavian R, Noorbakhsh Varnosfaderani SM, Aziziyan F, Liaghat M, Baziyar P, Yousefi Rad A, Tavakol C, Moeini AM, Nabi-Afjadi M, Zalpoor H, Kazemi-Lomedasht F. Inflammopharmacology 31 1029-1052 (2023)
- Experimental Technologies in the Diagnosis and Treatment of COVID-19 in Patients with Comorbidities. Amin MS, Wozniak M, Barbaric L, Pickard S, Yerrabelli RS, Christensen A, Coiado OC. J Healthc Inform Res 6 48-71 (2022)
- Interaction between coronaviruses and the autophagic response. Yu J, Ge S, Li J, Zhang Y, Xu J, Wang Y, Liu S, Yu X, Wang Z. Front Cell Infect Microbiol 14 1457617 (2024)
- Malaria, COVID-19 and angiotensin-converting enzyme 2: what does the available population data say? De A, Dash M, Tiwari A, Sinha A. Open Biol 11 210213 (2021)
- Nano-biosensor for SARS-CoV-2/COVID-19 detection: methods, mechanism and interface design. Liu Y, Qin Z, Zhou J, Jia X, Li H, Wang X, Chen Y, Sun Z, He X, Li H, Wang G, Chang H. RSC Adv 13 17883-17906 (2023)
- Non-symmetric stapling of native peptides. Chen FJ, Lin W, Chen FE. Nat Rev Chem 8 304-318 (2024)
- Peptide-Based Inhibitors of Protein-Protein Interactions (PPIs): A Case Study on the Interaction Between SARS-CoV-2 Spike Protein and Human Angiotensin-Converting Enzyme 2 (hACE2). Rakhmetullina A, Zielenkiewicz P, Odolczyk N. Biomedicines 12 2361 (2024)
- Repurposing of Plant-based Antiviral Molecules for the Treatment of COVID-19. Khazir J, Ahmed S, Thakur RK, Hussain M, Gandhi SG, Babbar S, Mir SA, Shafi N, Tonfack LB, Rajpal VR, Maqbool T, Mir BA, Peer LA. Curr Top Med Chem 24 614-633 (2024)
- Severe Acute Respiratory Syndrome Coronavirus-2 Cardiovascular Complications: Implications for Cardiothoracic Anesthesiology. Cormican DS, Winter D, McHugh S, Sonny A, Crowley J, Yu R, Barrack F, Núñez-Gil IJ, Ramakrishna H. J Cardiothorac Vasc Anesth 35 932-943 (2021)
- Structural Requirements and Plasticity of Receptor-Binding Domain in Human Coronavirus Spike. Li Y, Zheng P, Liu T, Shi C, Wang B, Xu Y, Jin T. Front Mol Biosci 9 930931 (2022)